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Hepatitis C is now a global health problem with an estimated 170 million people
infected worldwide. It is known to be the cause of the majority of cases of non-A,
non-B hepatitis. It is known to be progressive with at least 20% of patients
developing cirrhosis over 20 years. What is less clear is whether all infected people
with eventually develop complications and whether certain factors are important in
progression of this disease. There are other similar viruses that have been
characterised including HGV and their importance is not yet entirely clear.
The aims of this thesis were to:
Study the epidemiology and natural history of HCV infection in our population of
HCV infected patients in South East Scotland.
Investigate the factors important in progression of chronic HCV infection and also the
effects of chronic HCV infection on quality of life
Examine another novel flavivirus, HGV, in Scottish blood donors.
A database of all patients with chronic HCV referred to our hospital was set up. Data
was gathered prospectively and analysed with regards to demographic variables and
factors related to progression of disease. The importance of HLA status in
development and severity of disease was also examined. Finally the impact of chronic
HCV infection on QOL was assessed in a subgroup of this population.
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In a separate population the prevalence, natural history, clinical significance and risk
factors for transmission ofHGV were assessed.
262 patients were initially included in the database. 214 patients were HCV-RNA
positive and were investigated further. Various demographic variables were recorded.
Nearly 20% had cirrhosis on biopsy. Factors important in progression were age at
infection, male sex and alcohol consumption.
When HLA status and progression were examined certain antigens were found to
protect against development of chronic disease and cirrhosis.
Quality of life was found to be significantly impaired across all domains of life in
patients with chronic HCV infection.
HGV is common amongst Scottish blood donors but is not associated with significant






Hepatitis C vims infection (HCV) is now known to be responsible for 90% of the
cases of non-A, non-B hepatitis and nearly all those that followed blood transfusion. It
is the most common cause of liver disease in the United States and is estimated to
have infected 170 million people worldwide. It is now the most common indication
for OLT.
The vims was first cloned in 1989 (Choo et al 1989) and since that time considerable
progress has been made in characterising the stmcture and biology of the vims,
identifying the mechanism of hepatocellular damage, recognising the routes of
transmission and the development of sensitive and accurate diagnostic tests.
1.2 Prevalence
The prevalence of infection varies throughout the world. In the UK the prevalence is
estimated at 0.075%-1.5%, at 0.3% in North America and Western Europe, 0.5%-
1.5% in the Mediterranean and Eastern Europe and 2% in South America (Alter
1995). In Africa the figure is reported as between 0.6% and 1.5% and in Egypt up to
20%. In the East the prevalence varies from <1% in Australia, New Zealand and
China, to >2% in Japan and Saudi Arabia.
1.3 Transmission
The main route of transmission is parenteral. The highest incidence occurs in
intravenous dmg users (IVDU) and recipients of blood and blood products prior to
implementation of the screening regimens for blood donors.
16
Blood Transfusion
Prior to the introduction of HCV antibody testing in 1990 estimates of the frequency
of transfusion associated NANB hepatitis were available. These range from 0.5% in
UK to 3-4% in USA, 7.7% in Japan, 9.6% in Spain and 12.5% in Taiwan. Since the
implementation of blood donor screening with anti HCV the risk of post transfusion
hepatitis has significantly declined. The current estimated risk is between 0.05%-
0.017% per unit of blood. ( Donahue et al 1992; Kleinman et al 1992). With the
routine introduction of PCR testing the risk will further decline.
Patients who require repeated blood transfusions are at much higher risk of
contracting HCV infection. (Mozzi et al 1991, Locasciulli et al 1991).
Plasma Product recipients
Unfortunately a high proportion of haemophiliacs became infected with the virus
prior to the introduction of current methods of inactivation in pooled plasma products
and blood donor screening programmes. Haemophilia patients who have received
repeated transfusions with untreated or incompletely activated factor concentrates
have prevalence rates ofHCV in excess of 90%. (Rumi et al 1990; Troisi et al 1993).
Intravenous drug users.
As a result of needle sharing amongst IVDU the prevalence of HCV infection is
significant. In one Spanish group 86% were positive for HCV antibodies and of those
with less than one year of intravenous drug use the prevalence rate was 69%.
(Bolumar et al 1996). IVDU who have a longer duration of use, a history of needle
sharing and a history of imprisonment are at the greatest risk of infection. (Crofts et al
1993;Donahue et al 1991)
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Haemodialvsis patients
The prevalence in haemodialysis patients varies according to geographical area. In the
UK we have one of the lowest prevalence rates compared to a rate of 20-91% in
Eastern Europe. (Alter 1995). Several studies have shown an association between
increasing years on dialysis and rates of HCV antibody positivity. (Niu et al 1993;
Hardy et al 1992). This has been shown to be independent of blood transfusion and
could therefore reflect transmission between patients in dialysis centres perhaps
because of inadequate decontamination of equipment.
Organ Transplantation
HCV may be acquired prior to transplantation, from blood transfusion at the time of
transplantation (prior to blood donor screening) or from HCV infection in the organ
donor. In one study a transmission rate of nearly 50% occurred in patients
transplanted from HCV positive donors, (Pereira 1992).
Needlestick Injury
There are a number of case reports describing transmission of HCV infection after
occupational needlestick injury or cuts with sharp instruments. (Seef 1991;
Marranconi 1992; Cariani 1991). Overall 4-10% of needlestick injuries with HCV
infected blood result in transmission of infection. (Adter 1994; Mitsui et al 1992;
Kiyosawa et al 1991). Dentists (2%) and particularly those that do oral surgery (9%)
are at higher risk of contracting HCV infection. (Klein et al 1991).
The risk factors that seem to be associated with increased rate of needlestick
transmission in dental practitioners are type of needle (hollow versus solid), frequency
of occupational blood contacts, the type of patient (acute infection versus chronic
carriers) and prevalence ofHCV among patients (Memon et al 2002).
18
Other parenteral risk factors.
Other potential parenteral risk factors include tattoos using non-sterile needles, ear
piercing and previous immunisation.
Sexual transmission
Many studies of partners ofHCV infected patients have been undertaken and rates of
infection of 0-15% (average 5%) have been reported. (Bresters et al 1993;Osmond et
all993; Everhartet al 1990; Brettler et al 1992). Among non-IVDU prostitutes
prevalence rates of 4-12 % have been found. (Hadziyannis et al 1993, Mast et al
1991). Prevalence rates among homosexual males have been reported between 1-5%
and in non-drug using mostly heterosexual populations attending STD clinics
prevalence rates of 1-10% have been reported (Alter 1995).
In summary sexual transmission appears to be inefficient and uncommon although if
the patient is co-infected with HIV infection the rate of sexual transmission is higher.
Vertical Transmission
Vertical transmission occurs in less than 10% of children of infected mothers. A
recent review of published studies of mother to infant transmission found that the
factors associated with higher rate of mother-to-infant transmission were maternal co-
infection with HIV and history of previous drug abuse. Mode of delivery and
prevalence of breast-feeding did not significantly influence rates of mother-to-infant
transmission. Viral factors such as HCV-RNA titres and genotype have not been
consistently measured in studies and therefore their role is, as yet, unclear.
(Yeung et al 2001).
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Sporadic infection
Finally, in up to 20% of patients there is no apparent risk factor for HCV transmission
and is referred to as 'sporadic infection'. Some of this group may be those reluctant to
admit to previous intravenous drug use. In addition previous immunisation, dental,
treatment and alternative medical practices in other countries particularly Africa may
account for infection in some of these people. There may also be other routes of
transmission ofwhich we are currently unaware.
1.4 Virology
1.4.i HCV genome
The single positive sensed RNA genome of HCV is composed of approximately 9400
nucleotides with a single translational open reading frame (ORF) that spans 90% of
the genome (Choo et al 1989, Choo et al 1991, Takamiza et al 1991, Grakoui et al
1993a, Hijikata et al 1993a). A large polyprotein is produced by translation of this
ORF; this undergoes proteolytic processing by host cellular peptidases or viral
proteinases resulting in at least 9 viral proteins. (Figure 1.1).
The structural proteins C, El and E2/NS1 are released from the N terminal region of
the polyprotein following cleavage by host signal peptidases (Hijikata et al 1991). The
C protein is believed to form the viral nucleocapsid and is highly conserved among
HCV isolates (Houghton et al 1991, Okamoto et al 1992). The El and E2/NS1
proteins are the putative viral envelope proteins and contain a hypervariable region
(HVR), which may be used to identify HCV genotypes and quasispecies. This HVR is
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thought to occur by sequential mutation and be important in escape from host immune
surveillance resulting in viral persistence (Weiner et al 1992, Simmonds 1995).
The non-structural proteins are cleaved by two virally encoded proteases.
The NS2 protein contains a zinc-dependent metalloprotease, which initiates cleavage
at the NS2/NS3 junction (Grakoui et al 1993b, Hijikata et al 1993b). The remainder
of the polyprotein is further processed to NS3, NS4a, NS4b, NS5a and NS5b proteins
by the virally encoded serine protease contained in the N-terminal portion of NS3
(Hijikata et al 1993b, Tomei et al 1993, Bartenshlager et al 1994,Van Doom 1994).
In addition the NS3 protein has RNA-stimulated NTPase and RNA helicase activity

















More recently the function of the NS4A protein has been described. Firstly it anchors
NS3 to the surface of the endoplasmic reticulum; secondly it is an essential cofactor
for cleavage at the NS4B/NS5A and possibly the NS3/NS4A site and finally it
enhances cleavage at the NS5A/5B and NS4A/NS4B site (Tanji et al 1995, Lin et al
1995, Shimizu et al 1996).
The mechanism by which this occurs is unknown but the most likely explanation is
that the NS4A protein stabilises NS3 in an active formation. The function of the
NS4B and NS5A proteins has not been clarified but there is evidence to suggest that
the NS5B protein is a RNA-dependent RNA-polymerase essential for replication of
the viral genome (Van Doom 1994, Behrens et al 1996).
At either end of the genome is an untranslated region (UTR). There has been recent
interest in the 5' region as the site for an internal ribosomal entry site (IRES). It is
likely that translation of the HCV genome is similar to that of picornoviruses where
translation is cap-independent and commences at an IRES within the 5' UTR
(Tsukiyama-Kohara et al 1992).
1.4.ii genotypes
Sequence comparisons of HCV have allowed the identification and classification of
HCV into a series of genotypes that differ from each other in nucleotide sequence.
There are at least 6 genotypes identified and each of these may be further divided into
more closely related subtypes (Simmonds et al 1995, Bukh 1995).
These exhibit both epidemiological and geographical differences. Genotypes 1,2 and 3
are most commonly found throughout Western countries and the Far East, type 4 is
23
found predominantly in the Middle East and Central Africa, types 5 in South Africa
and type 6 in South East Asia (Simmonds et al 1997).
There has been considerable interest in the clinical significance of these genotypes.
With respect to disease progression there have previously been a number of studies
suggesting type lb is associated with a more severe and rapid progression of disease
(Booth et al 1995,Watson et al 1996, Kobayashi et al 1996); however other studies
have concluded there is no real evidence to support this and it may simply be that type
lb infected individuals have a longer mean duration of infection. (Dusheiko et al
1994, Yamada et al 1994). However there would appear to be more conclusive
evidence that type lb predisposes to the development of hepatocellular carcinoma.
(Haydon et al 1997, Tanaka et al 1996). There is also more definitive evidence that
genotype affects response to treatment with interferon-alpha and this will be discussed
in more detail in section l.lO.i.
1.4.ii quasispecies
In common with other RNA viruses that replicate through an RNA polymerase, HCV
circulates as a mixture of closely related genomes termed a quasispecies (Martell et al
1992). This therefore results in the establishment of several closely related but distinct
viruses within a single host. Quasispecies are distinct from genotypes in that over the
entire genome they show much lower levels of homology. The main clinical
importance is related to persistence of infection, and difficulties with developing an
effective vaccine. One paper has suggested that more diverse quasispecies are
associated with more severe and progressive liver disease. (Honda et al 1994).
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1.5 Pathogenesis and host immune response
The exact mechanism of hepatocellular damage in HCV infection is still unknown.
Some authorities believe that the virus is directly cytopathic and indeed there is some
evidence to support this view.
1.5.i Cytopathic mechanisms
The evidence for this includes:
HCV has some similarities to other members of the flavivirus family (Takamizawa et
al 1991, Miller et al 1990) and these viruses including yellow-fever virus are often
directly cytopathic.
The observation that alpha-interferon therapy causes rapid normalisation of serum
aminotransferases suggests that the drug is acting against a directly cytopathic virus.
Hepatic HCV-RNA levels have also been demonstrated to correlate with the
histological activity ofHCV infection (Lau et al 1993, Jeffers et al 1993).
However the current opinion is that immune-mediated injury is the main mechanism
of hepatocellular injury and that virus-mediated cytotoxicity is less important.
1.5.ii Immune mediated mechanisms.
The host immune response in patients with HCV is important for two reasons. The
first is its role in the elimination or attempted elimination of the virus and the second,
its role in hepatocellular damage. Both humoral and cell-mediated immune responses
have been demonstrated in patients with HCV infection.
Cell mediated immunity
T lymphocytes do not recognise native antigen. The antigen has to be processed,
usually by antigen presenting cells, and then presented on the surface of the cell in
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association with major histocompatability complexes (MHC) CD4+ T cells recognise
antigen bound to Human Leucocyte Antigen (HLA) class II molecules and CD8+ T
cells recognise antigen bound to HLA class I molecules.
CD4+ T cells
Most patients have a CD4+ response in the peripheral blood to one or more of the
HCV proteins, in particular to core and NS4 (Botarelli et al 1993, Ferrar et al 1994).
In the liver CD4+ T cells are present and can respond to both structural and non¬
structural proteins although the T cell receptors are different to those on the CD4+
cells in the peripheral circulation suggesting compartmentalisation of the T cell
response to the site of disease (Minutello et al 1993, Lohr et al 1994).
CD4+ T cells have several functions including production of cytokines, promoting
growth and differentiation of cytotoxic T lymphocytes (CTL) and activation of
inflammatory cells (Mosmann et al 1986). Patients with HCV infection have elevated
levels of these cytokines in serum and liver suggesting a role for these substances in
the immune response to HCV (Cacciarelli et al 1995, Reiser et al 1995).
CD 8+T cells
HCV specific CD8+ T cells have been found in both the hepatocytes and peripheral
blood mononuclear cells in patients with HCV infection (Kita et al 1993, Koziel et al
1993, Koziel et al 1992, Nelson et al 1996, Tsai et al 1994), but it appears that it is
those in the liver which mediate the major CTL response. CD8+ cells may cause
direct lysis of virally infected cells or stimulate cytokine-mediated damage. The
response seems to be diffuse against epitopes in different structural and non-structural
proteins
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CTL activity is important in both viral clearance and hepatocellular damage It is
therefore interesting to speculate that by attempting to eliminate HCV infected cells,
CTLs contribute to hepatocellular damage and that suboptimal or inefficient CTL
response results in persistence of infection. Evidence from immunodeficient patients is
inconclusive. HCV related chronic liver disease appears to progress more rapidly in
liver transplant patients receiving immunosupressant therapy whilst progression in
concurrently affected HIV patients is probably not accelerated.
Humoral immunity
The humoral immune response involves antigenic stimulation of B cells with
production of antibodies specific to viral proteins. There is evidence that this occurs in
HCV infection.
Intraportal lymphoid aggregates have been demonstrated in the livers of people
infected with HCV. These consist mainly of activated B lymphocytes in a germinal
centre surrounded by a dendritic cell network with a T lymphocyte zone of CD4+ T
helper cells and CD8+ T cells (Mosnier et al 1993).
Circulating antibodies are generated against several viral antigens. The development
of these antibodies in relation to elimination of HCV is still unclear, but they do not
appear to be neutralising. In a similar fashion to cell-mediated immunity the humoral
response may contribute to hepatocellular injury.
In conclusion both arms of the immune response are active in patients with HCV
infection. However neither appears to be able to eliminate the infection in the majority
of patients and it possible that the immune response significantly contributes to
hepatocellular damage.
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1.6 Histopathological findings in hepatitis C
1.6.i Acute HCV infection
Whilst the pathological findings in chronic HCV are well documented and reviewed
there is less information about acute HCV infection. In common with other hepatitis
viruses acute HCV induces liver cell injury and necrosis and causes a characteristic
response to that injury. On light microscopy ballooning degeneration, focal necrosis
and acidophilic bodies are seen. In severe cases necrosis of adjacent liver cells occurs,
usually in zone 3 resulting in bridging fibrosis. There is concurrent regeneration of
liver cells. Other features that may be seen are mild macrovesicular steatosis and
cholestasis. An inflammatory response involving Kupffer cells and lymphocytes is
seen. The most severe cases show extensive confluent necrosis producing submassive
or massive necrosis.
1.6.ii Chronic HCV infection
The pathological findings in chronic HCV infection whilst characteristic are not
specific. The predominant inflammatory cells are the lymphocytes.
The histological abnormalities can be divided as follows: -
Portal tract lesions
Portal tract changes include nodular aggregates of lymphocytes with germinal centres
and bile duct lesions
Portal lymphoid aggregates and lymphoid follicles that consist mainly of B-
lymphocytes are the characteristic finding in chronic HCV infection. It has been
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suggested that these are true functional lymphoid follicles that induce stimulation of
effector T cells and B cells. (Mosnier et al 1993).
Bile duct lesions occur in about a quarter of patients with chronic HCV infection.
These have similarities to the lesions of primary biliary cirrhosis however the ducts are
not destroyed and portal areas without ducts are rarely seen. Small or medium sized
bile ducts are infiltrated by lymphocytes and the bile duct epithelium undergoes focal
degeneration, necrosis and vacuolation. (Gerber et al 1995).
Piecemeal necrosis
This is thought to be the important pathological process in the progression of chronic
hepatitis. It is most easily recognised by irregularity of the limiting plate due to portal
inflammation extending through the limiting plate into the periportal parenchyma.
(Goodman et al 1995). Unicellular degeneration and necrosis is seen and cell death
occurs by apoptosis. As the chronic hepatitis progresses there is continuing erosion of
the hepatic parenchyma until small islets of hepatocytes become trapped in expanded
portal zones. Fibrosis gradually occurs which progresses to scars. The degree of
necrosis is used to grade the degree of activity.
Intralobular lesions
In the hepatic lobules steatosis (micro or macrovesicular), infiltration of sinusoids by
lymphocytes, apoptosis and extensive hydropic swelling of hepatocytes are seen. Mild
to moderate steatosis is typical of chronic HCV although not universal. (Scheuer et al
1992).
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In three reviewed studies bile duct damage was seen in 60%; lymphoid aggregates,
follicles or both in 57% and steatosis in 52%. It was surmised that a combination of
two out of the above three is seen in at least 50% of patients with chronic HCV and
can therefore be useful in the histological diagnosis of this disease. (Gerber 1994,
Bach et al 1992, Scheuer et al 1992, Gerber 1995)
Fibrosis and cirrhosis
Chronic hepatitis C appears to be a progressive fibrotic disease although the degree of
fibrosis varies from person to person. It is this progressive scarring that leads to
cirrhosis and the majority of complications associated with chronic HCV infection.
Progressive piecemeal necrosis results in collagen deposition and sinusoidal
cappillarisation. Portal to portal fibrous bridging occurs. In addition central to portal
and central-to-central fibrous bands may form. Contraction of theses fibrous bands
and nodular regeneration of the surviving parenchyma leads to cirrhosis.
Hepatocellular carcinoma
There is now a significant amount of evidence that chronic HCV infection is a major
risk factor for the development of hepatocellular carcinoma. Studies have indicated
that 13-80% of patients with HCC have positive anti-HCV antibodies. The
mechanism of hepatocarcinogenesis in chronic HCV infection is unknown however it
is speculated that the development of liver cirrhosis with continuing hepatocellular
necrosis, regeneration and chronic inflammation may be important in the malignant
transformation of hepatocytes.
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1.7 Natural history of HCV infection
1.7.i Acute HCV
Because acute infection with HCV is usually asymptomatic it is rarely diagnosed.
Only a minority of those infected appear to clear the virus and the remainder develop
chronic HCV infection with the risks of development of cirrhosis and its
complications and hepatocellular carcinoma.
Acute HCV results in malaise, nausea, dark urine and jaundice. Jaundice occurs in less
than 20% of those infected and the mean incubation period to onset of symptoms is 7
weeks (range 3-20 weeks). (Alter et al 1989, Barrera et al 1995).
HCV RNA becomes detectable in the serum from 1-3 weeks after exposure (Farci et al
1991) and HCV antibody within 6-8 weeks. After 2-5 weeks serum ALT begins to
rise and thereafter-clinical signs may become apparent. The severity is variable and
only one third of infected patients develop clinical signs and jaundice. It has been
observed that those who develop clinically apparent hepatitis seem to clear the virus
and therefore avoid the development of chronic disease more frequently than those
who do not. (Giuberti et al 1994).
1.7.ii Chronic HCV infection
The natural history of chronic HCV infection is complex. Progression to chronic liver
disease occurs in at least 80% of infected patients and the development of cirrhosis in
at least 20% of cases by 20 years after infection. (Alter et al 1992, Seeff et al 1992).
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Some experts believe that progression of chronic hepatitis C is inevitable from mild
chronic hepatitis through moderate to severe histological changes to cirrhosis and
then hepatocellular carcinoma however others believe that only a proportion of
infected patients will develop progressive disease and the challenge is therefore to
predict in whom disease will progress and concentrate treatment on that group.
There have been several studies of natural history to date and some of the most
important are highlighted here.
Seeff et al in 1992 studied patients with transfusion associated NANB hepatitis and
found no difference in mortality from all causes in those with TAH although there was
a small but statistically significant increase in the number of liver related deaths. (Seeff
et al 1992)
Alter et al in 1992 studied the natural history of community acquired HCV infection.
Their conclusion was that chronic hepatitis developed in a significant proportion of
patients with community acquired HCV infection and that HCV infection appeared to
persist for at least several years. (Alter et al 1992).
Tong et al in 1995 studied clinical outcomes in patients after transfusion associated
hepatitis and concluded that chronic TAH was a progressive disease and in some
patients led to death from liver failure or hepatocellular carcinoma. During the follow-
up period 20/131 (15.3%) of patients died; 19/20 (95%) from complications of
cirrhosis or HCC. (Tong et al 1995).
Di Bisceglie et al prospectively studied patients receiving blood transfusions during
cardiac surgery. 53/1070 became positive for anti HCV. They noted progression to
cirrhosis in a significant number of cases. (Di Bisceglie 1991)
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Niederau et al prospectively studied 838 patients with chronic HCV infection and
found an increased mortality compared with the general population mainly when
cirrhosis was present and when patients had contracted the disease at less than 50
years of age. (Niederau et al 1998).
More recently a systematic review was undertaken of published epidemiological
studies with the aim of estimating the rate of progression to cirrhosis and the factors
that affect it. (Freeman et al 2001). The estimated rate of progression to cirrhosis after
20 years of chronic HCV infection was calculated as 22% for patients attending
hepatology clinics, 24% for post transfusion cohorts, 4% for blood donor series and
7% for community based cohorts.
Overall it is apparent that the natural history of chronic hepatitis C infection is not as
yet fully defined. Current knowledge would suggest that the disease is progressive
over a variable time frame and that serious complications do not generally occur until
at least 20 years after infection. However it has become clear that there are certain
factors that may be important in the severity and rate of progression of liver disease.
Factors affecting progression of HCV-related liver disease
There are multiple factors that have been postulated to be important in HCV induced
liver disease. These can be divided into patient factors; virus factors and co-factors
(table 1.1).
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Patient Factors Virus Factors Co-Factors
Increasing age Increased virus level HBV infection
Mode of transmission
(blood transfusion)
HCV genotype lb HIV infection
Duration of infection Diverse quasispecies Alcohol abuse
Host HLA status
Table 1.1: Patient, virus and cofactors affecting severity and progression
of hepatitis C infection
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Patient factors.
Age at the time of infection appears to be important. Poynard et al in their study on
the natural history of liver fibrosis progression found that age at infection was the
main risk factor for fibrosis progression. (Poynard et al 1997). There are a number of
other studies that concur with this finding that age at time of infection has a significant
impact on development of advanced liver disease and liver-related complications.
(Tong et al 1995, Kenny-Welsh et al 1999, Freeman et al 2001).
Mode of transmission of infection has also been reported as being relevant. Several
authors have found that those infected through transfusion of infected blood had more
severe and progressive liver disease. (Alter et al 1992, Gordon et al 1993, Roudot
Thoraval et al 1997).
Male sex has been reported as being associated with a poorer outcome. Poynard et al
found that male sex was independently associated with fibrosis (Poynard et al 1997).
In addition in a recent epidemiological review, male sex was found to be one of the
three factors associated with more rapid disease progression (Freeman et al 2001).
Flowever several other authors have not replicated this observation other than the
association between male sex and the development of hepatocellular carcinoma.
(Niederau et al 1998, Fattovich et al 1997).
Flost HLA status. There has been considerable interest as to whether certain HLA
antigens are important in both the development of chronic disease and the progression
of liver disease in chronic HCV carriers. Several antigens have been found to be
protective against the development of persistent HCV infection (Congia et al 1996,
Zavaglia et al 1996). In addition several alleles have been implicated in the
development of cirrhosis. (Aikawa 1996).
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Virus factors
Genotypes. Until recently it was believed that genotype lb was associated with the
development of more severe disease. (Dusheiko et al 1995, Booth et al 1995,
Kobayashi et al 1996). However more recent studies have found no role for genotype
in disease severity and have suggested that the previous findings may be due to the
longer duration of disease associated in general with genotype lb. (Serfaty et al 1998;
Niederau et al 1998, Poynard et al 2001).
Virus level. Lau et al found that high HCV-RNA levels were associated with more
severe histological changes in the liver. (Lau et al 1993). Similar findings are reported
by other groups (Booth et al 1995; Hagiwara et al 1993) but as the level of viraemia
fluctuates it is unlikely that a single HCV-RNA level can be entirely predictive of
outcome. It has also been speculated that dose of initial innoculum is related to the
rate of progression of disease and that this accounts for some of the differences in
blood transfusion recipients (Roudot-Thoraval et al 1997). However more research in
this area is required.
Diverse Quasispecies. Honda et al examined the degree of diversity of quasispecies in
relation to progression of liver disease and found that the degree of diversity ofHCV
quasispecies was related to the progression of liver disease. (Honda et al 1994).
However more recent studies have failed to show any role in progression of liver
disease once chronic hepatitis has developed. (Seef et al 2002)
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Co factors
HBV appears to exert an additive effect on HCV in the progression of disease. There
are a number of reports indicating the role of HBV co-infection in the development of
cirrhosis and hepatocellular carcinoma. (Fong et al 1990, Alberti et al 1994, Benvegnu
et al 1994).
Co infection with HIV would appear to accelerate the development of liver
complications in patients co-infected with HCV (Martin et al 1989, Eyster et al 1993).
However HCV co-infection does not influence the rate of progression of clinical end-
points in HIV-infected drug users. (Haydon et al 1998).
Alcohol. There has been significant interest in alcohol as a co-factor in chronic HCV
disease. It appears likely that the combination of viral-injury and alcohol induced
injury predisposes to more severe liver injury than either agent alone. Ostapowicz
reported that on multivariate analysis total alcohol consumption was independently
associated with the presence of cirrhosis. (Ostapowicz et al 1998). Other authors
concur with this with excess alcohol consumption being associated with an increased
rate of fibrosis progression (Poynard et al 1997, Roudot-Thoravol et al 1997,
Freeman et al 2001) or decreased survival. (Niederau et al 1998). A more recent study
reported that a history of heavy alcohol use was strongly associated with an increased
risk of developing cirrhosis and that patients with both transfusion associated HCV
and a history of heavy alcohol use were 31.1 times more likely to develop cirrhosis
than controls with no history of alcohol abuse or HCV infection. Heavy alcohol intake




It is now accepted that chronic HCV infection is a major risk factor in the
development of hepatocellular carcinoma. This would appear to be restricted to those
with cirrhosis although the development ofHCC in patients without cirrhosis has been
described. (De Mitri et al 1995, Bralet et al 2000).
Many studies of natural history of HCV infection describe the risk of HCC in HCV
infected patients. In many regions HCV infection is the major risk factor identified for
HCC with up to 75% of patients testing positive for anti-HCV. (Di Bisceglie 1997).
The mechanism by which HCV induces the development of HCC is not known. In
HBV infection the DNA becomes integrated into host chromosomes and is thought to
have a directly carcinogenic effect. However as HCV is an RNA virus the mechanism
is less clear. Alcohol, infection with HBV, male sex and possibly genotype lb are
important co factors in the development of HCC in patients with HCV cirrhosis.
Yamauchi reported the 10-year rate of HCC was 19% in those with cirrhosis caused
by alcohol alone, 57% in those with HCV-related cirrhosis and 81% among those
with HCV infection who consumed more than 120g of alcohol per day. (Yamouchi et
al 1993).
The rate of progression to HCC from cirrhosis is more difficult to estimate. Di
Bisceglie estimated the risk of development of HCC from results of natural history
studies of HCV infection and studies on the development of HCC in patients with
HCV-related cirrhosis. He estimated that if 60% of patients exposed to HCV develop
chronic hepatitis and 20% of them develop cirrhosis within 10 years, approximately
12% of all patients infected with HCV would have cirrhosis and be at risk of
developing HCC. The risk of developing HCC is 1-4% per year which after 20 years
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would mean that 1.2%-4% of all infected patients would have developed HCC; 1.9%-
6.7% of those with chronic HCV and 9.6%-33.5% of those with cirrhosis would have
developed HCC. (Di Bisceglie 1997). Obviously the rate of development of HCC may
be higher once additional co-factors such as alcohol were taken into consideration and
with increasing duration of infection.
1.8 Extrahepatic manifestations of hepatitis C
Hepatitis C has been found to be associated with a number of extra-hepatic
manifestations. These include immunological disorders such as autoimmune hepatitis,
Sjogrens disease, glomerulonephritis, essential mixed cryoglobulinemia and
polyarteriris nodosa. (Lunel 1994, Pawlotsky 1994). The exact role of HCV in the
aetiology of these conditions is unclear.
There are a number of cutaneous associations of HCV including porphyria cutanea
tarda and lichen planus. There have been several different reports indicating the high
frequency of anti-HCV antibodies in patients with porphyria cutanea tarda up to 66%
in one series. (De Castro et al 1993, Murphy et al 1993).
Other associations include focal lymphocytic sialedenitis, Mooren corneal ulcer and
aplastic anaemia.
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1.9 Investigation in hepatitis C
Diagnostic Tests for hepatitis C
Diagnostic tests for HCV can be divide into two main groups:
serological tests that detect antibody to HCV
molecular assays that detect HCV RNA in the serum
1.9.i Serological assays
These can be further divided into screening tests and supplemental or confirmatory
tests.
Screening tests
Since the cloning of HCV in 1989 serological tests based on antibody detection have
been developed for the diagnosis of HCV infection. The main screening test is an
ELISA. The first generation antibody test incorporated a single HCV recombinant
antigen derived from the NS-4 region designated c 100-3. This assay lacked sensitivity
and specificity and was succeeded by the second and third generation assays that
incorporated other immunogenic areas of the virus. In 1992 the second generation test
was introduced which incorporated HCV antigens from the core and NS-3 regions in
addition to the NS-4 derived antigen. This resulted in a significantly improved
sensitivity but only a slightly improved sensitivity. With the introduction of the third





The third generation assay incorporates antigens from the core, NS-3, NS-4 and NS-5
regions. (Figure 1.2.)
However in view of the number of false-positive results particularly in low prevalence
groups such as healthy blood donors, introduction of confirmatory tests occurred.
Confirmatory tests
The supplementary assay developed for confirmation of these ELISA tests is the
Recombinant Immunoblot assay (RIBA). In this assay HCV antigens are immobilised
on nitro-cellulose strips. The RIBA-3 assay is now the most widely used and synthetic
peptides from the core and NS-4 regions and recombinant antigens from the NS-3 and
NS-5 regions are used. RIBA tests are interpreted as positive if there is reactivity to
one or more antigens and indeterminate if reactivity occurs to only one antigen.































However in several groups of patients antibody tests may not detect HCV infection. It
may take up to 6 months for an anti-HCV response to occur, the mean period for
antibody detection is 12 weeks. Also RIBA indeterminate patients need HCV
infection confirmed if present. In immunosuppressed patients, HCV infection may
occur without detectable antibodies and finally in perinatal transmission antibody tests
may not indicate actual transmission of infection. In all these groups detection of
HCV viraemia is necessary.
1-9-ii Molecular assays




As HCV -RNA is present in relatively low concentrations in the circulation the
nucleic acid has to be amplified. This is done by the polymerase chain reaction (PCR).
A portion of extracted viral RNA is transcribed into DNA and the number of DNA
molecules is amplified to a detectable level using primers, enzymes and temperature
cycling. Using primers from the 5' nontranslated region of the HCV genome increases
sensitivity. (Simmonds et al 1990).
The main problem with the technique is standardisation of assays. In one reported
survey only 16% of 31 European laboratories scored perfectly in a comprehensive
standardised test panel. (Zaaijer et al 1993).
qualitative tests
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This basically describes the detection of HCV-RNA by PCR techniques. Optimal
HCV-PCR assays have a sensitivity of less than 100 copies of HCV-RNA per ml of
plasma or serum.
quantitative tests
This describes the measurement of circulating HCV-RNA and therefore determines
the viral load. There are two main methods of doing this. Firstly quantitative PCR
where the target is amplified and secondly branched chain DNA signal amplification
assays where the signal is amplified rather than the target. The main problem of the
PCR technique is that amplification of the HCV-RNA prior to quantification can lead
to wide variation of results on the same sample. The main drawback of the branched
chain method is the lack of sensitivity. The main uses of the quantitative techniques
are in determining viral load, which may be relevant in the natural history of the
disease, and for monitoring response to treatment.
Genotvping
The clinical importance of genotypes in HCV infection remains controversial and their
use would appear to be most relevant in predicting treatment outcome, (section
l.lO.i). Methods of determining genotype are available and are now being more
frequently used when assessing patients for treatment.
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1.9.iii Liver function tests
Aminotransferases
ALT and AST are still used in the investigation of HCV infection. In acute hepatitis
their level is often raised with a similar pattern to other forms of acute hepatitis.
However in the chronic setting its value is more controversial. A significant number of
patients who are HCV-RNA positive and who have chronic hepatitis on liver biopsy
have a normal ALT value (Stanley at al 1996). In addition the level tends to fluctuate
and is not directly correlated with the degree of hepatic inflammation. The test is still
useful in assessing biochemical response to interferon-alpha therapy: if it normalises
during the first 2-3 months of therapy the patients is deemed a responder (if a patient
has a normal ALT then RT-PCR for HCV-RNA has to be used to assess response).
1.9.iv Histology
Because of the variable progression and natural history ofHCV infection liver biopsy
is a useful tool for staging disease and in some cases predicting prognosis. In addition
if patients have developed cirrhosis they can be entered into a screening programme
for hepatocellular carcinoma. A liver biopsy can aid the decision as to whether
interferon-alpha therapy might be of benefit to the patient.
Both the grade of inflammatory activity and the stage of fibrosis are determined. The
typical histological findings are discussed in section 1.6.ii.
1.10 Treatment




ALT Remains Transient Normalisation
abnormal decrease or
normalisation
HCV RNA in Remains positive Initially Negative for six
serum by RT- negative, then months after
PCR reverting to therapy
positive
HCV level by Unchanged Initial decrease, Undetectable
quantitative then reverting to
PCR pre-treatment
levels




Interferons are host proteins produced in response to infection with most viruses.
There are three main types of interferon, alpha (produced by B lymphocytes and
macrophages), beta (produced by fibroblasts and epithelial cells) and gamma
(produced by T lymphocytes that have been sensitised to foreign antigen). Interferons
have both antiviral (interrupting viral replication) and immunomodulatory (increasing
the number and activity of antibody producing cells and cytotoxic T lymphocytes and
also upregulating the expression of cytokine receptors on cells) activity.
Alpha-interferon was the first licensed treatment for chronic HCV infection in the UK
and USA. Its precise mechanism of action in this disease is unclear. Its efficacy in the
treatment ofNANB hepatitis was first analysed in 1986 (Hoofnagle et al 1986). Since
then many prospective, multicentre, randomised controlled trials have been carried
out. (Table 1.3) (Booth et al 1995, Hagiwara et al 1993, Saracco et all993, Reichard
et al 1994, Jouet et al 1994, Poynard et al 1995, Chemello et al 1995, Yamada et al
1995, Kasahara et al 1995,Sanchez-Tapias et al 1996).
Summarising these data, the response rate to a standard regimen (3 megaunits thrice
weekly for six months) of interferon therapy is 50%. However at the end of treatment
50% of these responders will relapse giving an overall sustained response rate of 25%.
In the earliest trials, response to interferon alpha was assessed only by normalisation
of serum aminotransferases. More recently virological cure has been defined as an
absence of HCV RNA from liver tissue, serum and peripheral blood mononuclear
cells although a disparity between biochemical and virological response is not
















































































































































































































































































































































































The initial recommendation for alpha-interferon therapy was three megaunits
subcutaneously, three times weekly for six months. There was, however, good
evidence that increasing the duration of treatment resulted in higher sustained
response rates (Saracco et al 1993, Poynard et al 1995, Kasahara et al 1995, Di
Bisceglie et al 1992, Kobayashi et al 1992). However increasing the dose above 3
megaunits does not appear to confer any therapeutic benefit. (Saraccp et al 1990,
Davis et al 1989, Marcellin et al 1991, Saez-Royvela 1991).
There are other important factors affecting response to treatment. Infection by HCV
genotype 1 (Kasahara et al 1995, Yoshioka et al 1992, Mita et al 1994), a high virus
level prior to therapy (Hagiwara et al 1993, Magrin et al 1994, Shibata et al 1993) and
the presence histologically of cirrhosis (Jouet et al 1994, Camps et al 1993) all appear
to significantly reduce the rate of sustained response. Monotherapy has now been
almost completely superseded by combination therapy although there are a group of
patients in whom ribavirin is contraindicated and who therefore continue to be treated
with monotherapy.
There has been considerable debate as to whether interferon alpha can modify the
natural history of HCV related cirrhosis. There have been conflicting results as to
whether interferon can prevent or delay the development of hepatocellular carcinoma
even inpatients who fail to respond to treatment (Nishigucchi et al 1995, Mazella et al
1996). Further studies have examined the effect of interferon therapy on preventing
other complications of cirrhosis. (Benvegnu et al 1998, Fattovich et al 1997, Camma
et al 1998). Many of these studies were retrospective. However a more recent
prospective trial was carried out with the aim of assessing the impact of interferon
treatment on the natural history of HCV cirrhosis. (Gramenzi et al 2001). This trial
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found that the natural history of cirrhosis was not significantly affected by interferon
treatment neither was it associated with an improvement in survival. However there
was a significant reduction in the cumulative incidence of hepatocellular carcinoma in
the treated patients when compared to the untreated group. The impact of treatment
was even greater in those patients achieving a sustained response.
There are several side effects known to occur with interferon-alpha therapy (table 1.4)
The mechanism of these is unclear.
Side-effects appear to have a dose response relationship. Identification of patients at
risk of severe side effects is important. In particular patients with underlying
psychiatric disorders have a high risk of neuropsychiatric complications of treatment,
which can be severe and associated with psychotic and suicidal thoughts.
Pegylated interferon
During the last two years long-acting interferons have been developed. The addition
of a polyethylene glycol (PEG) molecule to interferon alpha has resulted in a product
with better physical and thermal stability. This results in a longer half-life and enables
the interferon to be given once weekly. There are 2 PEG-interferons currently in use.
The first has a 12kDa linear PEG tail attached to interferon alpha2b and the second
has a 40kDa branched PEG molecule attached to interferon alpha2a. Used as
monotherapy both types are associated with an increased SR compared to standard
interferon alpha. (Lindsay et al 2001, Zeuzem et al 2000). In addition the PEG
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Table 1.4: Side-effects of interferon-alpha therapy
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l.lO.ii Alternative treatments
Because of the rate of relapse after interferon therapy the use of other agents both
alone or in combination has been examined.
Ursodeoxycholic acid
Ursodeoxycholic acid (urso) is a hydrophilic and non-toxic bile acid that has been
reported to reduce ALT in a number of chronic liver diseases e.g. primary biliary
cirrhosis. (Leuschner et al 1989, O'Brien et al 1991, Plevris et al 1991).
In HCV infection treatment with urso has been shown to result in a significant
reduction in serum ALT, however this was followed by a return to pre-treatment ALT
levels during follow-up. HCV-RNA titres were unaffected. (Puoti et al 1995, Attili et
al 1994). Combination treatment with urso and alpha-interferon does not show an
improvement in SR when compared with interferon treatment alone. (Angelico et al
1995, Boucher et al 1995).
Iron depletion
There are many reports of chronic HCV infection being associated with an elevated
hepatic iron content (Di Bisceglie et al 1992), and it has been postulated that the
efficiency of HCV therapy may be influenced by the amount of hepatic iron present
(Van Thiel et al 1994, Girelli et al 1995, Olynyk et al 1995). In addition it has been
reported that serum ALT levels decrease after phlebotomy alone in HCV infection.
However HCV-RNA levels were not assessed in this study and there was no evidence
of any histological improvement (Hayashi et al 1994).
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NSAID
Alpha-interferon plus ketoprofen (a NSAID) as combination therapy has been
demonstrated in a single study to produce an improved sustained response rate
compared with alpha-interferon alone (Andreone et al 1995), although no further
studies have reported similar findings.
Amantadine
Amantadine is an antiviral agent that has been used to treat influenza virus and has
also been shown to have activity against flaviviridae. Previous studies have suggested
that amantadine may have some effect against HCV either alone or in combination
with interferon. A recent study however found no significant increase in SR when
treatment with amantadine and interferon was compared with interferon monotherapy
(Caronia et al 2001).
Thymosins
Thymosins are hormone-like polypeptides processed by thymus epithelial cells. They
regulate maturation of T lymphocytes, stimulate CTL as well as CD3+ and CD4+
lymphocytes, modulate interferon production and stimulate the expression of
Interleukin-2 and its receptor.
Bovine thymus extract, which has similar properties to thymosin, has been used alone
in the treatment of HCV. Although it causes a reduction in aminotransferases there
was no significant sustained response rate (Civeira et al 1989). In combination with
alpha-interferon it seems to improve the overall sustained response rate (Sherman et al
1994). Zadaxin is an immunostimulant originally developed for the treatment of
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hepatitis B infection. It is composed of thymosin alpha-1 and alpha-interferon. A
phase III clinical trial conducted in Italy reported that 47% of patients treated with
combination therapy achieved a sustained response (both virologically and
biochemically) (Sciclone pharmaceuticals press release). Thymosin has been well
tolerated with no evidence of toxicity or drug-related side effects in over 1000
patients studied. A second phase III trial in the US produced disappointing results and
the development of the product was discontinued
Ribavarin
Ribavirin is a guanosine analogue with a broad spectrum of action against RNA and
DNA viruses including the flavivaridae (Patterson et al 1990). It is thought to inhibit
the normal transcription of mRNA although its mechanism of action in HCV is
unclear. Several studies have demonstrated that although serum ALT is significantly
reduced during treatment with ribavirin, six months after withdrawal of therapy the
serum ALT returned to its previous level. In addition HCV-RNA levels do not change
during or after treatment. Finally, there is no significant histological improvement
after ribavirin therapy. (Di Bisceglie et al 1992, Reichard et al 1991, Camps et al
1993, Dusheiko et al 1994, Bodenheimer et al 1994).
Combination therapy with ribavirin and alpha-interferon however has offered new
prospects in the treatment of chronic HCV infection and will be discussed in the next
section.
The modes of action of the drugs used in the treatment of chronic HCV infection are
summarised in table 1.5.
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Host Virus Notes
Alpha-interferon -Tnumber of Ab Effect on viral Exact mechanism
producing cells replication minimal of action unknown


































Table 1.5: Mechanisms of drugs used in chronic HCV infection
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l.lO.iii Combination therapy with ribavirin and interferon
In 1998 4 large international multicentre studies reported that combination therapy
with alpha-interferon and ribavirin was significantly more effective than interferon
monotherapy. Reichard et al found that 36% of interferon naive patients treated with
combination therapy for 34 weeks had a sustained response rate compared with 18%
in the monotherapy group. (p<0.05). (Reichard et al 1998). Poynard et al reported a
sustained response rate of 43% in their interferon-naive combination therapy group
(treated for 48 weeks) versus 19% in the monotherapy group (p<0.001). They also
found no significant difference in response rates between patients treated for 48 weeks
when compared to those treated for 24 weeks. (Poynard et al 1998).
However logistic regression identified 5 factors significantly associated with response
and in patients with fewer than 3 of these factors the odds ratio of sustained response
was 2.6 (95% CI 1.4-4.8; p=0.002) for the 48 week regime compared with 24 weeks
of the combination treatment, implying that patients with fewer favourable factors
benefit more from extending the duration of therapy to 48 weeks. McHutchison et al
reported a sustained response rate of 31% in patients treated with combination
therapy for 24 weeks versus 38% in those treated with combination therapy for 48
weeks versus 6% who received interferon monotherapy for 24 weeks and 13% in
those with interferon monotherapy for 48 weeks. (p<0.001 for the comparison of
interferon alone with both 24 weeks and 48 weeks of combination therapy).
(McHutchison et al 1998). Finally Davis et al treated patients who had previously
relapsed after interferon monotherapy. The sustained response in the combination
group was 49% versus 5% in the monotherapy group (p<0.001). (Davis et al 1998).
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Lower viral load was associated with higher rate of response in both treatment
groups.
Results of studies of combination therapy with PEG interferon are now being
reported. The initial two studies report broadly similar findings. Manns et al report a
SR of 54% for 48 weeks Rx with PEG interferon plus ribavirin versus 48% for
standard combination therapy. (Manns et al 2001). Fried et al report 56% versus 45%
for PEG combination therapy versus standard combination therapy. (Fried et al 2001).
Of note the overall incidence of side effects was comparable for both groups of
treatment.
The genotype of the patient is important when deciding on duration of treatment. It is
now clear that those with genotype 1 respond less favourably to treatment than those
with genotype 2 or 3. It has been shown that for patients with genotype 2 or 3, 24
weeks of treatment appears to be as effective as 48 weeks. For those with genotype 1
the best chance of SR comes with completing 48 weeks of treatment. The data for
combination therapy for genotype 1 with PEG interferon and ribavirin is not yet
available but is likely to represent a significant improvement on SR rates in this more
difficult to treat group of patients.
In summary with all the currently available data, patients with genotype 1 will benefit
from 48 weeks of combination therapy probably with PEG interferon whereas those
with genotype 2 or 3 probably only require 24 weeks of therapy.
1.11 Liver transplantation
End-stage cirrhosis secondary to chronic HCV infection is currently an indication for
orthotopic liver transplantation (OLT). The number of transplants undertaken for
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complications of chronic HCV infection is increasing world-wide. Unfortunately there
is a high (perhaps-universal) frequency of recurrence after OLT presumably because
of extrahepatic sites of HCV replication, which result in reinfection of the allograft
(Konig et al 1992;Feray et al 1994;Weinstein et al 1995). Early studies suggested that
despite a high rate of recurrent hepatitis, rates of graft survival were comparable with
those in other patients who had undergone OLT. However, a subsequent study (Gane
et al 1997) suggested that after extended follow-up, HCV infected patients may
develop more problems than patients who have undergone OLT for other indications.
There is agreement that HCV genotype lb is associated with an accelerated and more
aggressive graft hepatitis, (Feray et al 1995) but the significance of this in terms of
overall prognosis is unclear.
Although OLT increases the range of therapeutic options in chronic HCV infection,
reinfection of the transplanted allograft is probably universal and continued
monitoring of the disease is mandatory. Strategies of antiviral therapy after liver
transplantation are proving problematical as alpha-interferon may increase the rate of
graft rejection.
1.12 Vaccine Development
Infection with HCV leads to viral persistence in over 80% of patients despite a
cellular and humoral immune response to the virus. Quasispecies develop, which are
an attempt by the virus to evade the host's immune system.
In many viral infections the development of neutralising antibodies is associated with
recovery from infection and the induction of neutralising antibodies by vaccination is
sufficient to protect against viral infection. This does not seem to be the case in
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chronic HCV infection. Antibodies generated against the nucleocapsid region, NS3
and NS4 of the HCV genome are present in most people with chronic HCV infection
therefore they are unlikely to be neutralising.
Chimpanzees convalescent from infection with HCV are not protected against
challenge with homologous or heterologous HCV strains. This again suggests the
absence of a neutralising antibody response (Farci et al 1992).
Passive immunisation using HCV immunoglobulin in infected chimpanzees has been
demonstrated to prolong the incubation period of acute HCV infection but does not
prevent or ameliorate the HCV infection (Zuckerman 1995). Active immunisation
using recombinant DNA technology has been investigated. One company have used a
vector vaccine to attempt to induce neutralising antibodies against the putative
envelope proteins of HCV. Recombinant vaccinia viruses expressing the El and E2
proteins of HCV were used to infect mammalian HeLa cells in culture to produce
recombinant viral proteins. Five out of seven chimpanzees immunised with this
vaccine 30 to 40 weeks prior to challenge with a homologous HCV strain remained
disease free whilst in a control group all four chimpanzees developed hepatitis (Choo
et al 1994). There are however several limitations to this study. The challenge with
the virus was performed at the peak level of antibody production; the challenge dose
was a relatively low innoculum of virus and most importantly the question of
protection against heterologous strains was not addressed. Vaccine development is
underway however an effective vaccine will take more time because of the
quasispecies nature of HCV and the unanswered questions that exist about the role of
the host immune response to HCV.
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1.13 HEPATITIS G
It became apparent after the development of serological assays for hepatitis C virus
infection that about 20% of cases of community-acquired hepatitis (Alter et al 1989)
and 10% of transfusion associated hepatitis were not related to HCV infection (Alter
et al 1991). The search for further agents therefore continued. Two novel blood-borne
viruses were discovered independently by two groups of investigators and named
hepatitis GB virus C (Simons et al 1995, Leary et al 1996) and hepatitis G virus
(Linnen et al 1996). They have significant homology at the nucleotide and amino acid
level and are therefore thought to be isolates of the same virus. In this section the
viruses will be referred to as HGV.
1.13.i Prevalence
HGV was detected in 1.7% of blood donors in the USA (Linnen et al 1996) and
1.34% in German blood donors (Roth et al 1997). In our own Scottish blood donor
population the prevalence was higher with a reported rate of 2.25% in regular blood
donors. This study is presented later in this thesis.
In haemodialysis patients prevalence rates of 3.1-57.5% have been reported. (Masuko
et al 1996, De Lamballerie et al 1996).
With respect to fulminant hepatic failure HGV has been found in 0-50 % of patients
however it is possible that HGV could have been transmitted by transfusion in this ill
group of patients (Kuroki et al 1996, Sallie et al 1996)
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In intravenous drug users in Japan co-infected with HCV 24% also had HGV
detected. (Aikawa et al 1996a).
In homosexual males 31% were HGV-RNA positive and in prostitutes a prevalence
rate of 18% was reported. Both of these groups had denied previously injecting drugs.
(Scallan et al 1998).
In recipients of plasma products 14%of those who received non-virus inactivated
products were positive for HGV-RNA (Jarvis et al 1996). In another study of
haemophiliacs 25% of patients were HGV-RNA positive compared with 58/68 being
HCV positive. (Hanley et al 1998).
However in a study of the prevalence of HGV in patients with community-acquired
non A-E hepatitis only 9% of patients were positive for HGV-RNA. In addition it was
felt that the hepatitis in these cases might not be attributable to HGV. (Alter et al
1997).
The prevalence of HGV in chronic liver disease has also been investigated.
Approximately 5% of cases of chronic liver disease have a non-A-E cause.
Approximately 10% of these patients are positive for HGV-RNA. However HGV
RNA is detected as often or more often in patients who are infected with HBV, HCV
or both and when it accompanies chronic hepatitis C infection HGV does not affect
the severity of liver disease. (Miyakawa et al 1997).
1.13.ii Virus identification
HGV was isolated from a patient with non-A, non-B chronic hepatitis who was later
found to be infected with HCV. (Linnen et al 1996). GBV-C was identified using
primers from GBV-A and GBV-B, two viruses cloned from the serum of tamarinds
innoculated with serum from a surgeon (GB) with acute sporadic hepatitis (Simons et
al 1995). They are both positive single-stranded RNA viruses with a genomic
organisation similar to that of the flaviviridae and they are distantly related to hepatitis
C (they have 25% homology at nucleotide level). They share 86% of their nucleotides
and 96% of deduced amino acid sequences and are considered to be isolates of the
same virus.
Detection of HGV in serum relies on PCR amplification of HGV-RNA by reverse
transcriptase PCR. In the absence of accurate and reliable serological tests it is unclear
whether HGV persists in all infected patients although there are several reports of
HGV persisting for many years even up to 17 years. (Hanley et al 1997, Karayiannis
et al 1997, Masuko et al 1996).
1.13.iii Transmission
There certainly appears to be parenteral transmission of this virus as the prevalence
rates above indicate. Transmission of HGV has been identified through blood and
blood product transfusion, intravenous drug use and haemodialysis.
Vertical transmission has also been reported (Feucht et al 1996).
Sexual transmission is more controversial although in the study of homosexual males
and prostitutes reported previously the prevalence was significantly higher than that in
asymptomatic blood donors (Scallan et al 1998).
1.13.iv Natural history
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Prospective studies of transfusion-associated infections have shown that HGV RNA
can appear in blood recipients who were negative for the agent before transfusion;
transmission from donor to recipient has been clearly established. (Alter 1996).
However what is more difficult to elucidate is whether HGV causes hepatocellular
injury and indeed whether it is truly a hepatitis virus. Alter et al in a prospective study
showed that about 75% of HGV-infected transfusion recipients had no biochemical
evidence of liver disease. They also reported that in the few cases of hepatitis in which
HGV was the only agent identified the ALT elevations were quite small and there was
not a clear relationship between ALT levels and HGV-RNA levels. He further reports
that in patients co-infected with HCV and HGV, HGV has no influence on clinical
outcome and the ALT levels parallel those of HCV-RNA rather than HGV-RNA.
(Alter 1996). In a further study the relationship between HGV infection and ALT
levels in patients who were HGV-RNA positive and who had no other aetiological
factors for acute or chronic liver disease was studied. 45% had normal ALT levels and
55% had elevated levels. Of those with raised ALT, around a third had ALT levels
just above the upper level of normal. It was assumed that the chronic hepatitis in this
group was attributable to HGV infection. (Karayiannis et al 1997). However several
other groups have now reported absence of liver disease in patients with HGV
infection. (Neilson et al 1996, Masuko et al 1996, De Lamballerie X et al 1996).
Alter in his paper makes several observations. Firstly that most patients with
prospectively observed HGV infection have no evidence of resulting liver disease.
Secondly that although a number of cases of acute HGV infection were reported in
the community acquired study ofHGV infection, (Alter et al 1997) the persistence of
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viraemia after clinical and biochemical recovery may indicate that the patients were
chronic carriers ofHGV who had an acute unrelated episode of hepatitis.
Finally in studies of non-A-E hepatitis the prevalence of HGV is in the range of 3-
15% higher than in the blood donor population but similar to the rate in patients with
nonviral chronic liver disease (Alter 1996).
We can therefore currently conclude that there is no direct prospective evidence to
indicate that HGV causes acute or chronic hepatitis. However there is still the
possibility that HGV is a virus that may cause hepatitis under certain circumstances.
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2.1 Introduction
Chronic HCV infection has a worldwide prevalence of at least 1% (Alter 1995). The
natural history of chronic HCV infection is complex. Progression to chronic liver
disease occurs in at least 80% of infected patients and the development of cirrhosis in
at least 20% of cases by 20 years after infection. (Alter et al 1992; Seeflf et al 1992).
There is much interest as to what factors may be important in the development of
chronic HCV infection and in progression of the disease.
The aim of this chapter is firstly to examine and define the South East of Scotland
population of HCV infected patients referred to our unit in Edinburgh and secondly
examine progression to cirrhosis in our cohort of patients and identify which factors
are important.
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2.2 Subjects and methods
2.2.i database
This epidemiological study involved the collection and analysis of data relating to
patients presenting to our unit with a diagnosis of HCV infection between October
1995 and October 1997. All patients attending our clinic during this time who were
HCV ab positive were entered into the database. Patients were referred from a variety
of sources including local GPs, the community drug problem service, the infectious
diseases unit and the GU medicine clinic.
A standard proforma was used, (appendix 1).
Demographic details
Demographic details (including age, sex, place of referral) were recorded at the time
of the initial clinic appointment and at the time of biopsy.
Route of and duration of infection
Route of infection was classified into the following groups: IVDU, blood or blood
product transfusion, needlestick transmission, sexual transmission and sporadic.
Duration of infection was calculated as the time from age at infection to time of
biopsy.
Alcohol
Consumption of alcohol was also recorded. Patients were asked directly at clinic what
their consumption of alcohol had been per week for the previous five years. They
were then classified into one of three categories:
<21 units/week= minimal alcohol intake
21-50 units/week= moderate alcohol intake
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>50 units/week^ heavy alcohol intake.
Laboratory investigations
Parameters measured included:
Standard LFTs including bilirubin, ALT, alkaline phosphatase and gamma gluteryl
transferase.
HCV Ab status (by second generation enzyme immunoassayEIA-2, Abbot
Laboratories, Weisbaden, Germany) and third generation recombinant immunoblot
assay (RIBA-3, Chiron, Emeryville, California)
HCV-RNA status. This was performed by the University of Edinburgh virology lab.
RNA was extracted from 0.1ml of serum from each patient as previously described
(Jarvis et al 1994). Briefly, the RNA was pelleted by centrifugation at 100,000g for
90 minutes at 4°C and incubated at 37°C for 2h with lmg/ml proteinase K in the
presence of 40pg/ml of polyadenylic acid, 0.5% dodecyl sulfate, 0.1M NaCl, 50nM
Tris-HCl (pH8.0) and ImM of EDTA. RNA was extracted with phenol; after
centrifugation, the supernatant was extracted successively with phenolxhloroform
(1:1) and chloroforrmisoamyl alcohol (50:1). Nucleic acid was precipitated by the
addition of one-tenth volume of sodium acetate (pH 5.2) and 2vol ethanol. The dried
pellet was resuspended in 25 pi of diethyl pyrocarbonate treated water. RNA was then
reverse transcribed and amplified using nested primers matching the 5'-NCR (Chan et
al 1992). Products were cleaved with restriction enzymes and the fragments separated
by agarose gel electrophoresis using 4% Metaphor agarose.
HCV genotyping. This was performed by Dr Geoff Haydon. RNA was reverse
transcribed and amplified using nested primers matching the 5'-NCR. Product DNAs
were cleaved with restriction enzymes. The fragments were separated by agarose gel
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electrophoresis. Phylogenetic comparisons of sequences in the conserved region of
the genome confirm that 5'-NCR can be used to distinguish the six major genotypes.
(Haydon et al 1998, McOmish et al 1994)
Serological markers of HBV infection were detected with standard assays (RIA,
Abbott laboratories, Weisbaden, Germany).
HIV testing was performed using a third generation plus enzyme immunoassay
(Abbott, IL) with confirmation by Biokit ELISA (Biokit, Spain).
Histology
Liver biopsy specimens were assessed by two specialised liver pathologists.
Activity was graded according to intensity of necroinflammatory lesions (nil, mild
moderate, severe) (Bedossa et al 1996).
The stage of fibrosis was assessed on a 5 point scale. 0=no fibrosis, l=portal
spurring, 2=pericellular fibrosis, 3=bridging fibrosis and 4=cirrhosis. This scoring
system is based on the METAVIR scoring system which has previously been shown
to be highly reproducible among pathologists. (Bedossa et al 1994).
Treatment
Details of patients' treatment was recorded including dose, duration, response, side
effects and reasons for terminating treatment
Follow up
Follow up details were recorded prospectively including development of
complications relating to liver disease, OLT and death.
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2.2.ii analysis
Patients included for analysis were those that were both HCV-Ab and HCV-RNA
positive. Those that were HCV-RNA negative or that had data pertaining to HCV-
RNA status missing were excluded from analysis.
2.2.iii statistics
The chi-squared test and students t test were used to compare frequencies and means.
The cumulative probability of developing cirrhosis was calculated using the method of
Kaplan and Meier. All patients with biopsy data available and a known duration of
infection were included. Analysis of cirrhosis development was performed by
computing survival curves according to the Kaplan-Meier method. Development of
cirrhosis was considered as the end point. Curves were compared statistically using
the log rank test. Multivariate analysis of factors for development of cirrhosis was





A total of 262 patients were initially included in the database. 214 were HCV-RNA
positive, 35 were HCV-RNA negative and in 13 patients the HCV-RNA status was
unknown. Only those patients that were HCV-RNA positive were included in the
epidemiological analysis i.e. the study population comprises the 214 patients who
were HCV-RNA positive.
AGE
There was data regarding age at time of infection for 161/214 patients. The date of
infection for injecting drug users was taken as the date of first injection. It has been
previously demonstrated that the majority of IVDU contracted HCV in their first year
of injecting drug use. The date of exposure to a known risk factor such as blood
transfusion was taken as date of infection in the remainder of the patients. Patients
who contracted HCV infection through heterosexual, or sporadic routes make up the
majority of patients with unknown date of infection. The mean age at time of infection
in our patients was 25.2 (+/- 12.2) years.
SEX
In our cohort of 214 patients the sex difference was male 139; female 75.
72
MODE OF TRANSMISSION
The most common mode of transmission of infection in the cohort of patients is
intravenous drug use. The histogram demonstrating the modes of transmission is
shown in figure 2.1. The miscellaneous group includes needlestick injury, tattoos, ear
piercing and dental treatment.
There is a significant difference in the sex of patients who have contracted HCV
through drug use (with a significantly greater number of males than females
(p<0.05)). There is no significant difference in sex between patients who contracted
HCV infection through blood transfusion.
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Mode of transmission by sex
mode of transmission of infection
Figure 2.2
ALCOHOL
Alcohol consumption has particular relevance with regards to progression of disease
and development of cirrhosis. The alcohol consumption was classified as the amount
that had been consumed per week for at least five years. Three categories were
defined: minimal intake <21 units per week, moderate intake 21-50 units per week
and heavy intake greater than 50 units per week.
50.3 % of our patients were drinking less than 21 units of alcohol per week, 14.4%
were drinking between 21 and 50 units per week and 35.3 % were drinking greater
than 50 units per week.
There was a significant difference between alcohol consumption and sex. Males were
found to drink significantly more alcohol than females (p<0.001). (Figure 2.3).
COINFECTION WITH OTHER VIRUSES
16.7% of the HCV infected patients were coinfected with HIV. With regards to
hepatitis B infection, 69.9% had no markers for hepatitis B infection; 2.3% and <1%
were s antigen and e antigen positive respectively. 27.7% had evidence of previous
infection.
ALT VALUES
At initial clinic attendance 15.5% of patients had a normal ALT value (defined as less
than 40iu/l). 37.2% had levels up to twice normal and the remainder (47.3%) had
values greater than twice normal.
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Alcohol consumption by sex






Amount of alcohol consumed
Figure 2.3
GENOTYPES
Genotyping of 75 patients was performed and the distribution of these genotypes is
shown in figure 2.4. The most common genotype in those patients tested was 1
(54%).
DURATION OF INFECTION
Duration of infection is calculated as the time of infection to time of biopsy.The
duration of infection was able to be calculated in 144 patients. The median duration of
infection in our group of patients was 12 years.
HISTOLOGY
83.2% of our patients underwent liver biopsy and therefore have data on histology
available. As described earlier the histological findings were recorded according to
inflammation and fibrosis. This is shown in figure 2.5.
95 (55.9%) patients had mild inflammation, 66 (38.8%) had moderate inflammation
and 7 (4.1 %) had severe inflammation. 2 patients had no inflammation.
With regards to fibrosis 37 (20.8%) patients had no fibrosis, 30 (16.9%) had portal
spurring only, 56 (31.5%) had pericellular fibrosis, 20 (11.2%) had bridging fibrosis
and 35 (20.8%) had cirrhosis.
The relationship of alcohol to fibrosis was also examined. There was a strong
correlation of amount of alcohol consumed and degree of fibrosis on biopsy
(p<0.0001). There was also a significant correlation between amount of alcohol
consumed and degree of inflammation (p=0.005).
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Neither HIV status or hepatitis B status had a significant relationship with degree of
fibrosis or inflammation. Genotype also had no significant effect on histological
changes although the numbers were small (n=65).
Age at infection had no significant effect on degree of inflammation or degree of
fibrosis.
In this cohort of patients there was no significant correlation between level of ALT
and either degree of inflammation or amount of fibrosis.
Males were significantly more likely to have a greater degree of fibrosis than females
(p<0.05). This however was not the case with respect to degree of inflammation.
(Figure 2.6).
Regarding duration of infection there was a significant relationship between duration
of infection and degree of fibrosis however there was no significant relationship with
regards to level of inflammation.
Mode of acquisition of infection had no effect on either fibrosis or inflammation.
TREATMENT
65 patients underwent treatment with interferon-alpha.
Patients were treated using a standard treatment protocol. The treatment used was
alpha interferon 3 megaunits three times per week for a maximum of 6 months.
Of these 2 patients stopped treatment early because of side effects.
The remainder completed 6 months of therapy. There were 4 sustained responders
(defined as normalisation of ALT and absence of circulating RNA during treatment
and maintained at six months after completion of treatment).
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There were 23 non-responders (defined as no effect on ALT and HCV-RNA during
or after treatment).
There were 36 relapsers (defined as normalisation of ALT and absence of circulating
HCV-RNA during treatment followed by return ofHCV-RNA following cessation of
treatment. (Figure 2.7).
There was no significant difference in treatment responses according to mode of
infection, genotype, or ALT prior to infection however there was a significant
difference in response according to sex of the patient with females being significantly
more likely to respond than males (p<0.05), however there was no significant
difference in sustained response between males and females. (Figure 2.8).
OUTCOME
After 5 years follow up 22 patients had died
16 patients died from complications related to their liver disease, either hepatocellular
carcinoma or decompensated liver disease. 6 patients died from other causes including
suicide, lymphoma, stroke and death from violence.
4 further patients underwent OLT 2 for HCC and 2 for other complications relating to
decompensated liver disease. One of the patients transplanted for HCC died
subsequently
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Degree of fibrosis according to sex
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Figure 2.8
2.3.ii Progression of disease
Duration of infection was available in 144 patients. In this subgroup, progression to
cirrhosis was calculated. The progression to cirrhosis according to different variables
is illustrated in the following figures.
Progression according to sex
There was no significant difference in development of cirrhosis according to sex in
our cohort of patients. (Figure 2.9).
Progression according to route of infection.
There was no significant difference in progression to cirrhosis in IVDU versus
patients infected through blood transfusion. (Figure 2.10).
Progression according to alcohol consumption.
There was a statistically significant difference in progression to cirrhosis in patients
who consumed greater than 50 units of alcohol per week when compared to those
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Figure 2.11
Progression according to hepatitis B status and HIV status
There was no significant difference in rate of progression to cirrhosis in patients
infected either with hepatitis B or HIV infection. (Figure 2.12).
Progression according to age at infection
There was a significant difference in development of cirrhosis according to age with
patients infected after the age of 40 having a faster progression to cirrhosis p<0.0001.
(Figure 2.13).
Progression according to duration of infection
The overall progression to cirrhosis with time is demonstrated in figure 2.14.
The median time to development of cirrhosis in the overall cohort was calculated as
23 years (95% confidence interval 20.62 to 25.38)
Cox regression analysis
The independent risk factors identified for progression to cirrhosis were an older age
at infection (>40 years) and a previous alcohol consumption of greater than 50
units/week for at least 5 years.
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2.4 Discussion
These data summarise the demographic characteristics of the cohort of patients
infected with chronic HCV in South East Scotland. The factors relevant to
progression to cirrhosis are also examined.
In this geographical area there is a fairly large number of injecting drug users relative
to many other areas in the UK and this is demonstrated by the large percentage of
patients with IVDU as their mode of transmission of infection (64%). The low mean
age of infection is largely related to this fact as it is known that the majority of IVDU
begin injecting drugs in their late teenage years and early twenties. Co infection with
other parenterally transmitted viruses was not uncommon with 16.7% of patients
being coinfected with HIV and 27.7% having evidence of previous hepatitis B
infection. There were relatively few patients with active hepatitis B infection
presumably due to the much lower rate of chronicity of hepatitis B virus infection
compared to HCV infection.
The alcohol consumption in our cohort of patients was high in common with many
other studies and the role of alcohol as an important cofactor in the progression of
chronic HCV infection to cirrhosis will be discussed later. The relatively greater
consumption of alcohol by males was also noted.
We have data on liver histology on a significant number of the cohort (83.2%).
It is now apparent that while the degree of inflammation can fluctuate over time, the
development and progression of fibrosis is thought to be largely irreversible and that it
is this progression of fibrosis that results in the development of cirrhosis and its
complications e.g. varices, ascites and hepatocellular carcinoma. However the
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association between fibrosis progression and the necroinflammatory scores on liver
biopsy is controversial. It has been shown that on a single liver biopsy there is little or
no correlation between severity of necroinflammatory activity and degree of fibrosis.
(Poynard et al 1997, Poynard et al 2001). However in several recent studies an
association has been shown between the degree of necroinflammatory activity and
subsequent progression of fibrosis. (Ghany et al 2000, Alberti et al 2001). This is in
keeping with the findings in the cohort that more severe inflammation was associated
with more progressive fibrosis.
In the group of biopsied patients 20.8% had cirrhosis at the time of biopsy. The
median time to development of cirrhosis was 23 years. The majority of patients had
either mild or moderate inflammation (94.7%).
There was a strong relationship between alcohol consumption and degree of fibrosis.
This is in agreement with many other studies. (Poynard et al 1997, Roudot-Thoraval
1997, Verbaan et al 1998). In addition those with heavier alcohol consumption had
significantly more inflammation than those who consumed lower amounts of alcohol.
The significance of this is less clear. Genotype, hepatitis B status and HIV status had
no significant effect on either amount of fibrosis or inflammation. The results relating
to genotype may be in part due to the small numbers of our patients who had been
genotyped. However other groups have concurred with this finding (Poynard et al
1997, Verbaan et al 1998).
Age at infection had no significant effect on fibrosis or inflammation scores although,
in common with other studies, when progression to cirrhosis according to age at
infection was examined there was a significantly faster development to cirrhosis in
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those infected over 40 years of age in (figure 2.9). This is in agreement with other
studies. (Poynard 1997, Freeman et al 2001, Poynard et al 2001).
There was no correlation between ALT and degree of inflammation or fibrosis in our
cohort. It is well recognised that ALT fluctuates during the course of chronic HCV
infection (Alter et al 1992). Several studies have been performed assessing patients
with persistently normal ALT over several months and have confirmed that ALT
levels are a poor guide to liver histology with some patients with relatively advanced
histological changes having normal transaminase levels and vice versa. (Stanley et al
1996, Healy et al 1995, Naito et al 1994, Bruno et al 1994). However some
longitudinal studies have demonstrated that ALT titre at time of initial biopsy can be
correlated with progression of fibrosis (Ghany et al 2000). Marcellin et al showed that
patients with a mean serum ALT level of twice the normal range had a greater risk of
progression of fibrosis on a repeat liver biopsy 3 years later. (Marcellin et al 2001).
We have not performed sequential biopsies in our patients and therefore cannot
confirm this finding in our population.
With respect to sex of patients there was a significant relationship between amount of
fibrosis and male sex although the role of alcohol as an additional factor needs to be
examined. Poynard et al in their study had similar findings with regard to sex and
other authors have reported a similar relationship. (Poynard et al 1997).
Relatively few patients had undergone treatment with alpha-interferon. The definitions
of response are shown in table 1.2 .The sustained response rate was 6%, the non-
responder rate 35% and the relapser rate was 56%. 2 patients (3%) stopped treatment
because of side effects. Over all the sustained response rate with 6 months treatment
with 3 megaunits thrice weekly was disappointing. Our sustained reponse rates were
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obviously lower than many of the trials previously reported. This may be due to
different methods of patient selection, use of dosage regimens that are now known to
be suboptimal and perhaps differing compliance rates amongst people attending our
clinic and those taking part in clinical trials. Interferon monotherapy has now largely
been superseded by combination therapy with ribavirin and this has resulted in a
significant improvement in sustained reponse rates in our patients.
Our patients now receive 6-12 months combination therapy with ribavirin and
interferon alpha and the results so far are much improved with respect to sustained
response.
The natural history and progression of chronic hepatitis C is complex. There are many
cross sectional and retrospective studies in the literature examining the natural history
of the disease and progression to cirrhosis. Of interest also are those factors which
may accelerate, promote, prevent or delay progression to cirrhosis.
In this population we found no significant effect of gender on progression to cirrhosis.
This is in contrast to several other studies where male sex has been associated with a
more rapid progression of liver disease. (Bissell et al 1999, Poynard et al 2001,
Freeman et al 2001). It is interesting that we found higher scores in fibrosis in male
patients and it may simply be that duration of infection is longer in our group of male
patients.
It does now seem clear that age at time of infection has a significant effect on
progression of fibrosis in patients with chronic HCV infection. In our cohort there
was a highly significant relationship between age at infection and time to cirrhosis
with those infected at over 40 years having a significantly reduced time to
development of cirrhosis when compared with younger patients. Other groups report
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similar findings.(Poynard et al 1997, Freeman et al 2001, Poynard et al 2001). There
are various hypotheses as to why this occurs. These include impaired host defence
mechanisms, increased fibrogenesis or decreased fibrinolysis on older people.
The route of infection had no significant effect on progression to cirrhosis.
This concurs with several other studies although there are a few reports of accelerated
progression in patients infected by blood transfusion. (Alter et al 1992, Roudot-
Thoraval 1997). Overall however it is now thought unlikely that route of infection has
any significant effect on development of cirrhosis.
Excessive alcohol consumption is now known to result in more rapid progression of
disease in chronic HCV infection. In the Edinburgh cohort those who consumed
greater than 50 units of alcohol per week developed cirrhosis significantly earlier than
those who consumed less than 50 units of alcohol per week. There were also
significant differences in duration to cirrhosis in those who consumed either minimal
(<21 units per week) or moderate (21-50 units per week) amounts of alcohol when
compared to those who had heavy (>50 units of per week) alcohol consumption.
There was however no significant difference in development of cirrhosis when those
drinking minimal amounts of alcohol were compared to moderate alcohol consumers.
There are many other studies reporting broadly similar findings. (Table 2.1).
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Author Alcohol units Findings P value
Bellentani 1999 <30g/day, >30g/day Consumption of
>30g/day associated
with 3X higher risk
of cirrhosis
p<0.01













Westin 2002 <40g/day Higher consumption












RR 1.97 for fibrosis
and 1.18 for survival
Table 2.1: summary of studies reporting effects of alcohol on patients with chronic
HCV infection
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Although there are many studies that examine the risk of heavy alcohol use what is
less clear is whether moderate or even low alcohol intake is associated with a higher
rate of progression when compared to those that are completely abstinent from
alcohol. We have not shown any difference in progression between those drinking
<21 units per week versus those drinking 21-40 units/week. However we did not
separate those that were drinking no alcohol at all from the minimal alcohol group and
it would be interesting to compare progression to cirrhosis in patients entirely
abstinent from alcohol and those that drink either minimal or moderate amounts.
Coinfection with hepatitis B infection is relatively common in patients with HCV
infection. Several previous studies have examined the role of viral interference in dual
HBV and HCV infection. The results have been conflicting with some suggesting that
HCV possesses the strongest suppressant effect (Pontisso et al 1996, Crespo et al
1997) and other suggesting that HBV is more dominant (Ohkawa et al 1995, Wang et
al 1999). More recently a study from Taiwan has examined the role of 1TBV in acute
HCV infection. (Chu et al 2002). This group found that the incidence of persistent
HCV infection correlated with the underlying status of HBV replication. The
incidence of persistent HCV infection in chronic HbsAg carriers without active
replication was similar to that in non hepatitis B carrier patients. However acute HCV
infection in chronic HbsAg carriers with active replication rarely progressed to
chronic infection suggesting that the presence of active HBV-DNA replication could
inhibit the persistence of HCV infection and also antibody responses to HCV. A
further recent study from Spain has examined viral replicative interference. They
found that HBV-DNA and HCV-RNA levels were lower in co-infections than in
single infections. How these studies relate to progression of disease is less clear
however because there are several studies that demonstrate that HBV appears to have
an additive effect on the rate of fibrosis progression. (Tsai et al 1996, Pontisso et al
1998, Cacciola et al 1999). There was no significant effect on progression in our
cohort however the small numbers with active infection make our results difficult to
interpret.
Similarly with HIV infection co infection is not uncommon. There are now many
studies that have demonstrated that coinfection with HIV is associated with a more
rapid progression of HCV. (Benhamou et al 1999, Lesens et al 1999, Ragni et al
2001, Di Martino et al 2001, Thomas et al 2002). Again our numbers are small
making it difficult to draw firm conclusions on our cohort.
Finally the independent variables that were significantly associated with development
of cirrhosis were demonstrated in the Cox regression model as older age at infection
and heavy alcohol consumption.
In summary this chapter describes the Edinburgh HCV cohort and examines factors
that are important in progression to cirrhosis. With recognition of the factors
associated with progression of disease, screening for complications and the improving
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3.1 Introduction
Infection with the hepatitis C virus (HCV) is the cause of 90% of the cases of
non-A, non-B hepatitis and most of the cases of post transfusion hepatitis. The natural
history of the disease is complex with a wide spectrum of disease; Less than 10% of
patients develop acute illness, whilst at least 80% of infected patients develop chronic
liver disease ranging from minimal hepatitis to cirrhosis and, in a significant number,
hepatocellular carcinoma (Alter et al 1992). Factors postulated to be important in the
development and progression of chronic liver disease in HCV infection have been
discussed in chapter 1 and include viral factors (e.g. high virus level (Hagawara et al
1993, Booth et al 1995, Lau et al 1993), HCV genotype(Booth et al 1995, Dusheiko
et al 1994) and diverse quasispecies (Honda et al 1996, Farci et al 1996)), host
factors (e.g. age (Poynard et al 1997), mode of transmission (Alter et al 1992,
Gordon et al 1993, Roudot Thoraval et al 1997); duration of infection (Kiyosawa et al
1990)) and cofactors (e.g. Hepatitis B virus infection (Alberti et al 1994, Fong et al
1990, Benvegnu et al 1994), Human Immunodeficiency Virus infection (Martin et al
1989, Eyster et al 1993)and heavy alcohol intake (Poynard et al 1997,Roudot-
Thoraval et al 1997, Seef et al 1992)).
Consequently, the lack of efficient immune responses are almost certainly also
involved in the development and progression of chronic hepatitis C infection. It is
likely that differences in the immunogenetic background of infected patients might in
part account for the wide variation in disease progression observed amongst diseased
individuals. Previously, it has been demonstrated that polymorphisms of immune
regulatory genes on HLA class I and II molecules can influence the host's ability to
present or react to viral antigens.
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Studies from different geographical areas have supported the role of HLA-DR
molecules, in particular, in the pathogenesis of chronic hepatitis C infection. While a
protective role for HLA-DR5 (Zavaglia et al 1996) and DR2 (Congia et al 1996) has
been reported for North European populations, the presence of HLA DR5 has been
associated with a benign course ofHCV induced liver disease in Caucasians (Peano et
al 1994), while a similar role has been described for HLA-DR13 in Japanese HCV
carriers (Kuzushita et al 1996).
In this study, we investigated the distribution of common HLA class I and II antigens
in a Scottish population with chronic HCV according to the severity arrd persistence
of infection.
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3.2 Subjects and methods
3.2.i subjects
patients
Seventy-one patients (41 male and 30 female) were recruited for the study. All were
attending our hepatitis C clinic. Each patient was HCV-Ab positive and positive for
HCV-RNA by RT-PCR, HBsAg negative; no other cause had been identified for their
liver disease. Patients underwent diagnostic liver biopsy; which was examined by a
pathologist experienced in interpreting HCV associated liver disease and divided into
chronic hepatitis or cirrhosis. All patients were Caucasian and of North European
extraction to avoid ethnic HLA variability,
controls
The control population consisted of a cohort of 264 (132 male, 132 female) age
matched Scottish Caucasians described previously (Jazwinska et al 1987). Most
normal control data on HLA antigen frequency are derived from blood donors or
laboratory personnel. This control group were derived from healthy new parents
recruited at the Simpson Memorial Maternity Pavilion. The major bias could be that
the population is taken from a relatively narrow age range. To counteract this
possibility the researchers examined the neonatal antigen frequencies which were not
found to be significantly different from the parent group. This therefore excludes the
unlikely possibility of HLA associations with death before reproductive age and
infertility. It was therefore felt that this control group were an appropriate group to
use to compare with our HCV infected patients.
All patients recruited to the study gave informed consent and ethical approval was
obtained for the study.
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3.2.ii methods
Complete physical examination was performed in each case. Standard tests of liver
function and inflammation were obtained and repeated on at least 3 separate clinic
visits.
Each patient was typed for HLA class A, B and DR using a two-stage complement
dependent microlymphocytotoxicity technique as previously described (Terasaki
1980). (The majority of this work was performed by Mary McColl and Lorraine
Deane in the tissue typing laboratory, RIE)
Patients were tested for the following antigens common in the Scottish population.
A1,A2,A3,A11,A24; B7,B8,B35,B44; DR1 ,DR2,DR3,DR4,DR5,DR6,DR7
3.2.iii statistics
Comparison between HLA allele frequencies was performed by Chi-squared analysis.
P values were corrected (Pc) for the number of antigens used according to the method
ofBonferroni. Values of Pc<0.05 were taken as statistically significant.
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3.3 Results
71 liver biopsy results were available. 17 patients (24%) had biopsy proven cirrhosis
and 54 (76%) had chronic hepatitis including portal inflammation, lobulitis and
fibrosis. Of the patients with chronic hepatitis 13/54 (24%) had a normal ALT value
on 3 or more consecutive occasions. The remainder (41) had an elevated level.
The distribution ofHLA class A, B and DR frequencies in the study population of 71
patients and the population of264 normal controls is shown in tables 3.1-3.3.
Table 3.1 shows the frequencies in the healthy population versus the HCV infected
patients. Table 3.2 illustrates the HLA frequencies in patients with chronic hepatitis
and a normal ALT value versus those with chronic hepatitis with an elevated ALT
level. Table 3.3 reports the HLA frequencies in patients with chronic hepatitis on liver
biopsy versus those with biopsy proven cirrhosis.
Healthy versus HCV infected patients
We found that the frequency ofDR5 was significantly higher in the normal population
(12%) compared with HCV infected patients (0%) (Pc=0.006) suggesting that the
presence of the DR5 allele protects against the development of chronic disease.
Normal ALT versus raised ALT
DR6 was significantly associated with persistently normal transaminases (Pc<0.05)
while B7 and DR7 were associated with abnormal transaminases (Pc<0.0016).
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Chronic Hepatitis versus cirrhosis
HLA B35 occurred significantly more frequently in those patients with chronic
hepatitis (13%) when compared with those with cirrhosis (0%) (Pc<0.005),
suggesting that presence of the B35 allele protects against the development of








A1 37 97 32 23 NS
A2 50 131 53 38 NS
A3 31 81 21 15 NS
All 13 33 4 3 NS
A24 14 37 18 13 NS
B7 33 86 38 27 NS
B8 31 80 19 14 NS
B35 12 32 10 7 NS
B44 28 73 36 25 NS
DR1 10 27 14 10 NS
DR2 29 77 34 24 NS
DR3 31 83 29 21 NS
DR4 25 66 26 19 NS
DR5 12 33 0 0 0.006
DR6 35 93 25 18 NS
DR7 33 86 34 24 NS









A1 46 6 32 13 NS
A2 66 8 54 22 NS
A3 7 1 27 11 NS
All 0 0 2 1 NS
A24 15 2 21 9 NS
B7 15 2 41 17 <0.0016
B8 15 2 24 10 NS
B35 15 2 12 5 NS
B44 30 4 32 13 NS
DR1 7 1 17 7 NS
DR2 41 5 32 13 NS
DR3 7 1 34 14 NS
DR4 30 4 24 10 NS
DR6 38 5 19 8 0.048
DR7 15 2 39 16 <0.0016
Table3.2: Frequencies of HLA antigens in patients with normal ALT
versus abnormal ALT
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HLA LOCUS HEPATITIS CIRRHOSIS Pc
% n % n
A1 35 19 23 4 NS
A2 55 30 47 8 NS
A3 22 12 23 4 NS
All 1 1 11 2 NS
A24 20 11 11 2 NS
B7 35 19 47 8 NS
B8 24 12 11 2 NS
B35 13 7 0 0 0.0032
B44 31 17 41 8 NS
DR1 15 8 11 2 NS
DR2 33 18 35 6 NS
DR3 27 15 35 6 NS
DR4 26 14 29 5 NS
DR6 24 13 29 5 NS
DR7 33 18 35 6 NS




In this study, we have examined HLA class A, B and DR antigens in 71 Scottish,
HCV infected individuals and compared the results with a well-defined age and sex-
matched control population. The results suggested that certain antigens HLA DR5,
DR6 and B35 may protect against the development of chronic disease, significant
inflammation and hepatic cirrhosis respectively. Conversely, other antigens, HLA B7
and DR7 may predispose to the development of hepatic inflammation.
The role of host HLA antigens has been examined in other liver diseases, autoimmune
chronic active hepatitis (AICAH), primary biliary cirrhosis (PBC), primary sclerosing
cholangitis (PSC) and chronic hepatitis B infection. DR3 and DR4 contribute to
susceptibility to AICAH (Donaldson et al 1991a, Doherty et al 1994, Seki et al 1992)
whilst in PBC, DR8 has a strong association with disease development in Japanese
patients (Maeda et al 1992) but only a weak association in European and North
American populations (Begovitch et al 1994, Gores et al 1997). In PSC, DR3 may
predispose to the development of disease (Donaldson et al 1991b) The associations in
hepatitis B infection are less convincing with several groups finding no association
(Zavaglia et al 1996, Czaja et al 1996, Verdon et al 1994) but two groups reporting
positive associations (Almarri et al 1994, Thursz et al 1995).
There have now been several studies examining the role of host HLA status in chronic
HCV infection. There has been and still is significant interest in whether certain HLA
antigens or alleles predispose to or, more importantly, protect against the
development of chronic HCV infection. In the first of two Italian studies an HLA
DR2 subtype was identified as protective against the development of chronic HCV
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infection in Sardinian multiply-transfused patients (Congia et al 1996). In the second
study the DR5 locus was significantly more common in healthy controls versus
patients with chronic hepatitis implying it is a protective factor against the
development of chronic disease (Zavaglia et al 1996). These data fully concur with the
findings of this study where 12% of our healthy controls had the HLA-DR5 allele
versus none of our HCV infected patients.
The gold standard for HLA typing is now recognised to be DNA typing. When
carrying out this study DNA typing was not routine in our laboratory and there were
various technical problems with DNA extraction. For these reasons this study was
conducted using only the microlymphocytotoxicity technique described above. Other
authors subsequently have investigated the distribution of HLA subtypes and alleles
using the polymerase chain reaction and sequence specific primers. Tibbs and his
group were the first to demonstrate the importance of host HLA DQ alleles. They
concluded that DQB 1*0302 and DQB1*03 were associated with protection from the
development of chronic HCV infection in their Northern European cohort (Tibbs et al
1996). An Italian group reported that the haplotype
DRB1*1104,DQA1*0501,DQB1*0301 protects against the development of chronic
disease and the transdimer DQA1*0201 DQB 1*0201 predisposes to the development
of chronic and persistent HCV infection (Zavaglia et al 1998). These studies all
suggest a role for the HLA class II antigens DR and DQ in the protection from or
susceptibility to the development of chronic disease in patients infected with HCV.
The role of host HLA status and disease inflammatory activity has also been
examined. DR5 was associated with a more benign course of disease in North
American patients (Peano et al 1994) while a similar role has been described for DR13
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in Japanese HCV carriers (Kuzushita et al 1996). In our cohort, HLA DR6 was
significantly more common in patients with persistently normal ALT compared with
the population with raised transaminase levels thus perhaps affording protection
against severe disease. In all three studies the populations were either symptom free
individuals with persistently normal ALT or with chronic hepatitis on liver biopsy and
abnormal transaminase levels. However the value ofALT titre in predicting degree of
inflammation is controversial (as discussed in chapter 2). More recently evidence has
emerged that suggests that a persistently normal ALT may be associated with a
slower rate of progression to cirrhosis. (Mathurin et al 1998, Freeman et al 2001).
This may therefore suggest that DR6 in our population is associated with a more
benign course of disease i.e. slower progression to cirrhosis and that patients with the
B7 and DR7 antigens have a more rapid progression of disease to cirrhosis.
Finally in our study, HLA B35 antigen was protective against the development of
cirrhosis. Results from previous studies have once again been inconsistent;
DRB 1*0405 and DQB 1*0401 are associated with an accelerated progression to
cirrhosis while DRB 1*0901 and DQB 1*0303 appear to protect against the
development of cirrhosis in Japanese patients (Aikawa et al 1996). This study did not
examine class I alleles. However in several other studies using PCR and sequence
specific primers no link between progression of disease and HLA type has been
demonstrated (Tibbs et al 1996, Zavaglia et al 1998). Therefore the association of
FILA phenotype with progression of disease in chronic HCV infection is perhaps more
controversial than the link between phenotype and protection from development of
the disease.
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The mechanism by which HLA class II molecules affect the outcome after infection
with HCV is also unclear. However it is likely that that it is related to the function of
HLA molecules in the host immune response. HLA class II recognition is necessary
for T helper cell activation. In HCV infection the T cell mediated response is believed
to play an important role in liver damage. It may be that differing ability of HLA
molecules to bind and present viral antigens results in the differences in immune
response such that certain HLA types confer protection from or susceptibility to the
development, and progression of this infection.
In conclusion, we have demonstrated that HLA class I and particularly class II
antigens may influence the hosts' susceptibility or resistance to HCV. In vitro
investigations using HCV antigen presentation to T cells through HLA molecules may
ultimately aid in the development of immunotherapy or vaccination in HCV infection.
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CHAPTER 4




Quality of Life is a qualitative multidimensional concept that theoretically
incorporates a quantitative assessment of an individuals well being. In 1947 the World
Health Organisation defined health as 'a state of complete physical, mental and social
well-being and not merely the absence of disease or infirmity' (Constitution ofWorld
Health Organisation). The term Health related Quality of Life (HRQOL) is now
commonly used and numerous generic and disease specific instruments have been
developed to measure it. The realisation that objectively measured disease does not
necessarily bear a direct relationship to subjectively experienced illness has, in part,
led to this rapid expansion of interest. There is, however, concern about the
significance ofQuality of Life data and it is clear that Quality ofLife instruments need
to be both valid and reliable (Fallowfield 1996).
Early prospective studies of chronic hepatitis C virus (HCV) infection suggested that
it was a benign asymptomatic disease with no significant effects on long-term
mortality (Seeff et al 1992). However it is now well established that chronic HCV
infection is directly associated with the development of chronic hepatitis, cirrhosis,
hepatocellular carcinoma (Fattovich et al; 1997, Alter et al 1992, Hopf et al 1990, Di
Bisceglie et al 1991, Takahasi et al 1993, Tong et al 1995) as well as diverse
extrahepatic manifestations (Agnello et al 1992, De Castro et al 1993, Johnson et al
1993). Therefore it might be expected that this chronic progressive disease would
have a direct impact on Quality of Life.
In this study, we aimed to measure Quality of Life in a Scottish population of HCV
infected patients and to compare the results with a healthy control population
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4.2 Subjects and methods
4.2.i Subjects
The population studied consisted of three groups:
HCV infected patients
One hundred consecutive patients with chronic HCV infection attending our chronic
hepatitis clinic were recruited for the study. All were HCV-Ab and RT-PCR positive
for HCV RNA. All patients approached to take part in the study agreed.
No patients were being treated with alpha-interferon at the time of the study.
Four questionnaires were used. The format of them was explained at the clinic and the
subjects asked to return them by post. A single postal reminder to those patients who
had not returned their questionnaire by 3 weeks after their clinic attendance was sent.
72 (72%) of patients returned their questionnaires completed.
The routes of transmission were recorded and divided into intravenous drug use
(IVDU) (n=32), blood transfusion (n=21), sporadic (n=ll), sexual transmission
(n=5), others/unknown (n=3).
The liver function tests including alanine aminotransferase (ALT) was measured on
the day the questionnaire was handed out.
Age at time of infection (if known) and alcohol intake were recorded. Duration of
infection (if known) was calculated.
Of the 72 completed questionnaires 57 patients had previously undergone liver biopsy
and the disease stage by fibrosis and inflammation was recorded.
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Healthy controls
The healthy controls did not have health problems and were not taking any regular
medication. They were matched for age and level of education achieved and the same
four questionnaires were used.
All patients gave informed consent and ethical approval was obtained for the study.
4.2.ii Methods
measures
All subjects completed four questionnaires. These four questionnaires were selected
for use in this study because they have been previously documented to be valid and
reliable and the two Quality of Life questionnaires give a general overall objective
assessment ofwell-being.
The Medical Outcomes Study Short Form 36 (SF36)
The World Health Organisation-Quality ofLife Questionnaire (WHO-QOL)
The Hospital Anxiety and Depression Scale (HAD)
The Bentall Inventory (measuring fatigue)
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SF-36
This is a 36-item instrument, which takes only 5-10 minutes to complete (Ware et al
1992).
It was originally constructed to survey health status in the American Medical
Outcomes Study. It was designed for use in clinical practice and research, health
policy evaluations and general population surveys. It includes one multi-item scale




2 limitations in physical activities due to health problems
3 bodily pain
4 general health perceptions
mental health
5 social functioning
6 limitations in usual role activities due to emotional problems
7 general mental health (psychological distress and well-being)
8 vitality
Each of the eight domains is scored out of twenty. Higher scores indicate better
health.
It was designed for either self-administration by persons of 14 years or older or for
administration by a trained interviewer in person or by telephone.
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There have been many studies examining the validity and reliability of this
questionnaire in a variety of populations.
In one postal survey there was considerable evidence for the reliability of the SF-36
and for construct validity in terms of distinguishing between groups with expected
health differences. (Brazier et al 1992).
Cross sectional data from the Medical Outcomes study were analysed to test the
validity of the SF-36 scales as measures of physical and mental health. Scales shown
to primarily measure physical health (physical function and role physical) best
distinguished groups differing in severity of chronic medical condition and were the
most valid for pure physical health interpretation. Scales shown to primarily measure
mental health: (mental health and role limitations-emotional) best distinguished groups
differing in the presence and severity of psychiatric disorders and had the most pure
mental health interpretation. The social function, vitality and general health scales
measured both physical and mental health and therefore had the most complex
interpretation. (McHorney et al 1993).
A further study was carried out to assess the reliability, validity and acceptability of
the SF-36 in the NHS in the UK. This reported that the SF-36b satisfied rigorous
psychometric criteria for validity and internal consistency. Clinical validity was shown
by the distinctive profiles generated for four separate medical conditions each of
which differed from that in the general population in a predictable way. (Garratt et al
1994).
Finally a study was carried out to determine the criterion validity of the SF-36 in a
large community sample in the U.K. Internal consistency of the domains was found to
be high. Criterion validity was assessed by comparing scores for the seven dimensions
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assessing functional status and well being with the score from the single general health
dimension. Significant trends were observed for decreasing SF-36 scores (indicating
greater health problems) with worsening self-rated general health. (Jenkinson et al
1994).
This instrument is included in appendix 2.
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WHO-QOL
This instmment has been developed by the World Health Organisation to assess
quality of life across different cultures. The WHO defines quality of life as an
individuals' perception of their position in life in the context of the culture and value
systems in which they live and in relation to their goals, expectations, standards and
concerns. It is a broad ranging concept affected in a complex way by the person's
physical health, psychological state, level of independence, social relationships,
personal beliefs and relationship to salient features of the environment." (WHOQOL
group 1993, Kuyken et al 1994).
The WHOQOL-100 contains 100 questions over six broad domains of quality of life
within which 24 facets are covered.
The six domains include:
1 physical health
2 psychological




Four items are included for each facet, as well as four general items covering
subjective overall QOL and health producing a total of 100 items in the assessment.
All items are rated on a five point scale. (Table 4.1)
The WHOQOL instrument is said to place primary importance on the perception of
the individual. By focusing on individuals own views of their well-being, the
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instruments ask not only about the functioning of people with certain
diseases/disorders but also how satisfied the patients are with their functioning and
with effects of treatment.
The WHOQOL-lOO has been tested using psychometric procedures and shows high
levels of reliability and validity. In one study the WHOQOL was completed by a
sample of adults who represented 16 disease categories. The scores of the scale were
found to discriminate well between sick and well people and to concur with reported
health status. It concluded that the WHOQOL shows excellent overall internal
consistency reliability and can be used with individuals. The level of reliability
extended to all domains and patient subgroups. (Skevington 1999).
Field studies with this instrument are still ongoing however it does appear to have
cross-cultural validity and to be a reliable and valid measure ofQOL.
The instrument is included in appendix 2.
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DOMAIN FACETS INCORPORATED WITHIN
DOMAIN
Physical health Energy and fatigue
Pain and discomfort
Sleep and rest




Thinking, learning, memory and
concentration
Level of independence Mobility
Activities of daily living
Dependence on medicinal substances
and medical aids
Work capacity




Freedom, physical safety and security
Health and social care: accessibility
and quality
Home environment
Opportunities for acquiring new
information and skills





Spirituality/religion/personal beliefs Rehgion/spirituality/personal beliefs
Table 4.1: Facets ofWHOQOL questionnaire
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HAD
This is a well-validated measure of anxiety and depression (Zigmond et al 1983). It
consists of a brief scale of anxiety and one of depression. There are 14 items on two
subscales -7 anxiety items and 7 depression items. It was designed to avoid symptoms
that may appear in both anxiety and depression and in tests of reliability and validity
scores were not affected by the presence of a physical illness. Items such as insomnia,
fatigue, anorexia or weight loss, which could be symptoms of a physical disorder,
were excluded.
It is a brief self-assessment questionnaire, which is easily understandable and
acceptable to patients. It has been demonstrated to be equally effective in hospital,
out-patient or community settings.
There are many data on reliability and validity that are summarised in a previous
review. (Hermann 1997).
The instrument is included in appendix 2.
BENTALL INVENTORY
In 1993 Bentall published a brief nine-item fatigue inventory which has excellent
internal consistency and which is now widely used. (Bentall et al 1993)
This instrument is included in appendix 2.
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4.2.iii Statistics
Statistical differences between groups were assessed using the Mann Whitney U Test
or the Kruskal-Wallis 1-way Anova. In view of the multiple comparisons made the





Seventy two (72%) of the HCV patients (35 male, 37 female) returned their
questionnaires completed whilst 33 (100%) healthy controls (7 male, 26 female)
completed questionnaires. 70/72 (97.2%) HCV patients completed their
questionnaires fully, and 31/33 (94%) of healthy controls completed all parts of the
questionnaires.
There was no significant difference between age and level of education achieved
between the two groups. Table 4.2.
4.3.i Interpopulation analysis by measure of QOL
(1) SF-36
The subpopulation of patients with HCV infection scored significantly lower (i.e. their
health was worse) scores in all eight domains of the SF-36 when compared with




level of education achieved





Postgraduate education 0 (0%)








Table 4.2:Demographics of subjects
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100 (10) 87.5 (45) 0.002 *
Role physical 100 (0) 62.5 (100) <0.001 *
Role
emotional
100 (0)) 83.35 (100) <0.001 *
Social function 100 (6.25) 62.5 (50) <0.001 *
Mental health 80 (14) 72 (36) 0.001 *
Bodily pain 100 (21) 62 (59) 0.001 *
Vitality 80 (17.5) 50 (37.5)) <0.001 *
General health 90 (17.5) 52 (52) <0.001 *
*=Pc is significant (<0.008)
Table 4.3: SF36 results; HCV versus normal.
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(2) WHOQOL
Patients with HCV infection had significantly lower scores (i.e. indicating worse
health) in five out of six domains of the WHO-QOL when compared with healthy
controls. There was no significant difference between scores for the spirituality facet
between the two groups (table 4.5). In addition there was a highly significant
difference between the two groups with regard to overall function.
When compared with patients with IDDM the HCV infected patients had significantly
lower scores in the categories of physical domain and overall function. There was
however no significant difference between the two groups with respect to
psychological development, level of independence, social relationships, environment
or spirituality, (table 4.6).
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17.0 (2.5) 14.0 (4.6) <0.001 *
Psychological
development
15.6(3.1) 14.6 (4) 0.023 ns
Level of
independence
19.0(1.5) 15.6 (6.25) <0.001 *
Social relationships 16.7 (3) 15.7 (3.85) 0.003 *
Environment 16.1 (2.1) 15.0 (3.1) 0.011 ns
Spirituality 14.0 (5) 13.9 (6) ns *
Overall function 17.0(3) 13.5 (6) <0.001 *
*=Pc is significant (p<0.008)
Table 4.4: WHOQOL HCV versus normal
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(3) HAD
Although there was a significant difference in the HAD anxiety and depression scores
between the HCV infected group and the healthy controls, the median scores for the
HCV infected patients, IDDM patients and healthy controls fell within the normal
range (less than 7). (table 4.7,4.8).
(4) BENTALL
There was no significant difference in the Bentall scores between the HCV infected











HAD A 4 (4.5) 7.0 (7.75) <0.001
HADD 1 (3.0) 3.5 (6.5) <0.001
BENTALL 3 (3.5) 5.0(10) ns
Table 4.5:HADS; HCV versus normal
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4.3.ii Intrapopulation analysis of patients with chronic HCV infection
Route of transmission of infection
The population of patients with chronic HCV infection were divided according to
route of infection. There was no significant difference in QOL scores across all
domains of both the SF36 and WHOQOL according to route of infection. (Tables 4.6
and 4.7 respectively). There was also no significant difference in HAD A and D and
Bentall scores between different routes of infection.
Alcohol intake
When quality of life and alcohol intake were examined there was no significant
difference between alcohol intake and quality of life across all domains and in both the
SF36 and WHOQOL questionnaires. (Tables 4.9 and 4.10)
Histology
There was no significant difference between level of fibrosis and quality of life scores
across all domains. There was also no significant difference between level of
histological inflammation and QOL score. (Table 4.11 and table 4.12)
ALT score
When the HCV infected group were divided according to ALT (normal (<40),
moderately elevated (40-80) or high (>80)) there was no significant difference






















92.5 (23.8) 75.0 (65) 95.0(31.2) 100 (5) ns
role
physical
50.0 (93.8) 25.0 (100) 100 (75) 100 (100) ns
role
emotional
83.5 (100) 83.1 (100) 72.9 (100) 100 (83.5) ns
social
function
81.2 (62.5) 62.5 (50) 81.2 (56.2) 75 (43.8) ns
mental
health
76.0 (38) 74.0 (36) 72.0 (31) 72 (18) ns
bodily pain 83.0 (58.8) 62.0 (33) 67.0 (66.5) 100 (37.5) ns
general
health
54.7 (53.2) 46.0 (49.5) 62.0 (30) 72 (33.5) ns
vitality 50.0 (40) 50.0 (33.8) 60.0 (37.5) 70 (35) ns






















13.5 (4.5) 14.3 (4.2) 15.3 (6) 16.7 (4.2) ns
Psychological
development
15.4 (3.4) 15.5 (5.6) 15.4(4) 13.8 (2.8) ns
Level of
independence
16.6(5.9) 15.4 (6.8) 18.2 (5.1) 16.5 (3.4) ns
Social
relationships
16.0(4.8) 16.0 (6.4) 15.5(5) 16.0 (2) ns
Environment 14.8(2.3) 15.9 (2.2) 15.4 (3.9) 14.5 (2.3) ns
Spirituality 11.5 (8) 12.5 (6) 14.5 (5.5) 16.0 (8) ns
Overall
function
12.0(7) 14.0 (4.2) 15.0 (4.5) 14.0 (5) ns

























HADA 7.0 (8.5) 6 (7.8) 7.5 (8) 5 (5.5) ns
HADD 3.0(6.8) 4 (8.2) 2.0 (4.8) 4(5) ns
BENTALL 7.5 (10.2) 5 (9.8) 3.0 (9.8) 3 (7.5) ns




















85.0 (40) 90 (67.5) 90.0 (33.8) ns
Role
physical
50.0 (75) 100 (100) 12.5(100) ns
Role
emotional
100 (83.5) 100 (100) 66.7 (100) ns
Social
function
68.8 (50) 87.5 (50) 62.5 (71.9) ns
Mental
health
72.0 (28) 74 (41) 70.0 (35) ns
Bodily pain 67.0 (59) 84 (58.2) 51.5 (74) ns
General
health
52.0 (47) 64.5 (65.8) 53.5 (55.8) ns
Vitality 50.0 (32.5) 60 (55) 50.0 (47.5) ns

















14.0(3.7) 14.0 (7.2) 14.2 (8) ns
Psychological
development
14.8(4.4) 15.0 (6.7) 14.5 (3.5) ns
Level of
independence
15.5 (5.2) 16.8(8.9) 16.0(8.4) ns
Social
relationships
16.0 (2.9) 15.6 (7.3) 15.2 (2.7) ns
Enviromnent 15.1 (3.2) 15.2 (4.5) 14.9 (3.2) ns
Spirituality 13.0(4.5) 13.5 (9) 11.0(7.8) ns
Overall
function
14.0 (5) 14.0 (6.5) 12.0(8) ns











95.0 (27.5) 72.5 (35) ns
Role physical 100 (75) 0 (93.8) ns
Role
emotional
66.7 (100) 66.5 (100) ns
Social
function
75.0 (50) 56.2 (71.9) ns
Mental health 72.0 (35) 74.0 (36) ns
Bodily pain 67.0 (59) 57.5 (53) ns
General
health
62.0 (47) 37.5 (55.8) ns
Vitality 52.5 (38.8) 50.0 (52.5) ns











14.0 (5) 13.7 (7.3) ns
Psychological
development
14.8(3.6) 15.5 (5.8) ns
Level of
independence
16.4 (5.4) 12.7 (7.7) ns
Social relationships 15.5(4.1) 16.2 (5.9) ns
Environment 15.1 (3) 14.8 (4.6) ns
Spirituality 13.0 (6.2) 12.0 (6.2) ns
Overall function 13.0(6) 14.0 (8) ns
Table 4.12: WHOQOL by histology
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Duration of infection
Patients were also stratified according to duration of infection. (0-10, 11-20, 21-30
and > 30 years). There were no significant differences seen across all domains of both
questionnaires.
Age at infection
Age at infection when available was also recorded. Patients were stratified (<25, 26-
40 and >40 years old). Those infected over the age of 40 years had significantly worse
scores in SF36 physical function and vitality compared to those who were infected




















92.5 (30) 95 (30) 25.0 (52.5) P=0.001
Role
physical





83.4 (100) 100 (33.8) 16.5 (100) ns
Social
function
62.5 (75) 75 (50) 50.0(31.2) ns
Mental
health
70.0 (36) 76 (32) 64.0 (44) ns
Bodily pain 68.0 (59) 74 (38) 41.0(60.5) ns
General
health
47.0 (53.2) 67 (42) 37.0 (31) ns
Vitality 50.0 (46.2) 55 (35) 32.5 (32.5) ns

















13.5 (4.8) 14.7 (5.7) 14.0 (2.5) ns
Psychological
development
14.7 (5.2) 15.4 (3.4) 13.6 (5.8) ns
Level of
independence
16.0 (7) 17.5 (4.5) 10.2 (7) ns
Social
relationships
15.3 (5.4) 16.0 (2.3) 14.7 (5.5) ns
Environment 14.6 (4.2) 15.4 (2.4) 15.6 (2.8) ns
Spirituality 12.5 (7.5) 13.0 (7) 12.0 (6.5) ns
Overall function 13.0 (7) 14.0 (6) 13.0 (6) ns
Table 4.14: WHOQOL by age at infection
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4.4 Discussion
In this study we have demonstrated that chronic HCV infection has a
statistically significant effect on the majority of domains of Quality of Life as assessed
by two separate Quality of Life measures when compared with healthy controls. This
difference is not simply explained by anxiety or depression.
There have now been several other studies examining quality of life in patients with
HCV infection.
Rodger examined the impact of a diagnosis ofHCV infection in an Australian cohort.
They used the SF36 questionnaire. They found that patients with a known diagnosis
of HCV infection scored worse in 7 out of 8 domains when compared with healthy
controls. They also found that patients infected with HCV but unaware of the
diagnosis of HCV infection had impaired QOL across 3 of 8 scales compared to
healthy controls.(Rodger et al 1999).
Ware et al in 1999 used a different questionnaire the Hepatitis Quality of Life
questionnaire part of which was comprised of the SF36. Chronic HCV infected
patients had worse scores in physical functioning, role physical, general health, vitality
and social functioning when compared to healthy population normals. (Ware et al
1999).
Bonkovsky evaluated 645 patients. They examined QOL before and after treatment
with interferon-alpha. They used the SF36 and also incorporated additional items that
evaluated perceptions of appetite, cognitive functioning, current health status, feelings
of health distress, sexual functioning and sleep quality. Their data indicated that at
baseline patients scored low on all measured domains. The greatest reductions were
found in those scales that reflected physical impairment. Treatment resulted in
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improved scores in those patients who has a sustained biochemical and virological
response however those improved scores were still less than those of healthy controls.
(Bonkovsky et al 1999).
The sickness impact profile was used by Davis to assess HRQOL in HCV infected
patients before and after treatment with alpha-interferon. The authors concluded that
patients, before treatment commenced, had significantly worse scores in all categories
of the SIP (except eating) when compared with healthy controls. After treatment was
completed there was a significant improvement in several domains of the SIP whereas
in the untreated control group no significant difference was demonstrated between
baseline and the end of treatment values. Further, the authors concluded that although
the SIP was a reliable and valid instrument to measure impact of chronic HCV
infection on FIRQOL, further trials in patients with HCV infection should use a more
disease specific and responsive instrument .(Davis et al 1994).
Carithers modified the SF-36 by adding further questions to several of the domains.
Psychometric evaluation indicated it to be both reliable and valid. Patients with
chronic HCV infection scored significantly lower (i.e. worse) than the general
population in each domain and lower than patients with hypertension in 7 of 8
domains. When compared with patients with type II diabetes mellitus they scored
significantly lower in the vitality, bodily pain and social function domains, which
concurs with our findings. The authors demonstrated no correlation between objective
measures of disease activity and severity and subjective findings. (Carithers et al
1996).
The SF36 questionnaire was used in a further study (Foster et al 1998). They found
that patients with chronic hepatitis C were polysymptomatic and had significant
149
reductions in their SF36 scores for all of the modalities tested. This study compared a
hepatitis C subpopulation with a hepatitis B subpopulation and demonstrated that
although the HBV infected patients had a reduction in the SF36 scores that assessed
mental functions, there was no decrease in scores measuring physical symptoms,
indicating that the symptoms described by cohorts infected by FfBV and HCV are
qualitatively different. The authors were also unable to demonstrate a reduction in
Quality of Life attributable to the degree of inflammation or the mode of acquisition
of the infection.
We used four different instruments to examine Quality of Life as well as anxiety,
depression and fatigue. The SF-36 and WHO-QOL measure Quality of Life over a
series of independent domains, which together encompass the definition of Quality of
Life. This study examined Quality of Life in chronic HCV infection using more than
one instrument and our results, which correlate well across both measures used,
indicate that Quality of Life is genuinely impaired in patients with chronic HCV
infection.
Importantly, the study also demonstrated that there was no significant correlation
between route of transmission of infection and QOL score and this implies that it is
the HCV infection per se rather than any high risk behaviour (e.g. in IVDU) which
affects QOL. This is in agreement with other authors. (Foster et al 1998)
We also examined histological stage of liver disease using degree of fibrosis and
inflammation. We found no significant effect on QOL according to either severity of
inflammation or fibrosis. There was also no significant effect of presence of cirrhosis
on QOL although all the patients with cirrhosis were still well-compensated. This
again is in agreement with other investigators, (Foster et al 1998, Carithers et al 1996,
Bonkovsky et al 1999). Duration of infection had no significant effect on scores this
would seem logical given that more progressive disease does not appear to be
associated with a poorer QOL. However interestingly those infected over the age of
40 years of age had worse scores of physical function and vitality than those infected
at a younger age. The reason for this is not entirely clear.
Alcohol intake was also assessed and was found to have no significant effect on QOL
scores. This is in concurrence with a recent study in patients with cirrhosis of different
aetiologies. (Marchesisi et al 2001).
The observation that Quality of Life scores were not significantly related to ALT is
not surprising since there are now many data demonstrating that the ALT titre in
chronic HCV infection is not related to disease stage, severity or activity (Puoti et al
1997, Stanley et al 1996).
The third instrument the HAD scale measures anxiety and depression. Although there
were significant differences in the scores of the HCV infected group and those of the
healthy controls; all the median scores were within the normal range implying that
none of the two groups had clinically significant anxiety or depression. This then
suggests that the hepatitis C virus per se rather than other factors (e.g. anxiety or
depression) impairs quality of Life in affected individuals. Fatigue is a common
complaint in many physical diseases and indeed in the general population but is it is
particularly common in patients with certain chronic liver disease (e.g. primary biliary
cirrhosis). However there was no significant difference demonstrated between the two
populations using the Bentall Inventory perhaps because fatigue becomes a more
prominent symptom once the liver disease has decompensated. However others more
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recently have found a significant difference in fatigue scores using other instruments
e.g. the fatigue assessment instrument (Obhrai et al 2001).
What is less clear however, is why there should be such an effect on QOL in these
patients. Why does persistent hepatitis C affect how a person feels? It has been
postulated that the presence of viraemia and viral replication may be the cause of this
impaired QOL. Other theories include release of pro inflammatory cytokines e.g.
tumour necrosis factor-a, interleukinip and interleukin-6 either by the virus itself or
by pathophysiological events occurring directly as a result of the infection e.g.
hepatocyte damage and necrosis.
In summary we have demonstrated that chronic HCV infection has a significant effect
on how patients feel, their ability to function and on their life overall. This effect does
not appear to be correlated with disease activity measured biochemically and
histologically and is not related to anxiety, depression or fatigue.
Further studies are required to examine the relationship between biological factors
(e.g. proinflammatory cytokines), viral factors (e.g. viral load and genotype) and
QOL. It is also important to clearly define the effect of treatment on QOL and




CHARACTERISTICS OF HEPATITIS G VIRUS/GB
VIRUS C INFECTION IN SCOTTISH BLOOD DONORS
J 53
5.1 Introduction
Hepatitis C vims (HCV) has been identified as the principle cause of post
transfusion hepatitis (PTH) (Choo et al 1989), while the development of serological
tests for blood donor screening (Kuo et al 1989) has led to a dramatic fall in its
incidence. However in 10% of cases of PTH and 20% of community-acquired
hepatitis no aetiological agent has been identified (Alter et al 1992, Alter et al 1997b).
Recently a novel flavivirus, termed GB virus-C was identified using primers derived
from conserved regions in the viruses GBV-A and GBV-B which infect tamarinds and
other new world primate species (Leary et al 1996). Another group reported the
detection and characterisation of hepatitis G vims (HGV) from a patient with non-A,
non-B chronic hepatitis who was later found also to be infected with HCV (Linnen et
al 1996). GBV-C and HGV have significant nucleotide and amino acid sequence
similarities (85%, 97%) and are now accepted to be different isolates of the same
vims.
HGV/GBV-C is a positive single-stranded RNA vims with genomic organisation
resembling that of the flaviviridae family (Choo et al 1991, Kato et al 1990).
However, it appears to differ significantly from HCV in the epidemiology and natural
history of infection as well as the consequences of chronic infection. In this study we
aimed to determine the prevalence of HGV/GBV-C in large sample of the Scottish
donor population, determine the natural history of infection with the vims and assess
the clinical significance and possible risk factors for transmission of infection in
HGV/GBV-C positive donors.
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5.2 Subjects and Methods
5.2.i Subjects.
From October 1996 until December 1996, 1020 blood samples were collected from
volunteer blood donors attending the Edinburgh and South East Scotland Blood
Transfusion Service centre in Edinburgh. Samples were taken from consecutive
regular donors who had given written informed consent (32 of 1052 donors
approached did not agree to take part in the study). All subjects were seronegative for
human immunodeficiency virus (E1IV), hepatitis B virus (1TBV) and HCV.
All HGV/GBV-C positive donors were contacted and invited to attend for counselling
and further investigation. At their initial consultation repeat sampling for plasma
HGV/GBV-C RNA and ALT was undertaken, and a history of risk behaviour sought.
In addition a sample of saliva was collected for testing for HGV/GBV-C RNA.
Partners of infected donors were also invited to attend. All positive donors were
referred to a single hepatologist for clinical evaluation.
Each HGV/GBV-C RNA positive plasma sample was tested for antibodies to HBV
core protein (Amerlite anti-HBc assay) and human cytomegalovirus (HCMV, Captia
CMV-enzyme immunoassay, Centocor). Approximately one year after initial testing,
recalled donors were retested for HGV/GBV-C RNA by PCR.
Ajrchived samples from previous donations were retrieved and tested for HGV/GBV-
C RNA. The first two donations were tested (i.e. most distant in time) and if both
were negative, intermediate samples were retrieved and tested.
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5.2.ii Methods
This work was carried out by Professor Simmonds and his team at the Department of
Medical Microbiology, University ofEdinburgh.
Detection of HGV/GBV-C RNA and antibody in plasma. Unless otherwise
indicated, DNA was extracted directly from 100 ml ofEDTA anti-coagulated plasma,
and redissolved in 25 ml nuclease-treated water, of which 5 ml was used for PCR.
Citrated plasma was collected from blood donors, and combined into pools of 10
before extraction and testing by PCR. Positive pools were subdivided into component
donations and re-tested. Initial screening identified 23 positive pools, which led to the
identification of one positive component donation in each. RNA was also extracted
from 100 ml volumes of saliva samples as described for plasma samples. Viral KNA
was amplified by PCR using primers from the 5' non coding region (Jarvis et al 1996).
Quantitation was carried out by titration of the cDNA prepared from the nucleic acid
as previously described (Jarvis et al 1996). IgG antibodies to GBV-C/HGV E2-
antigen were detected using the PLATE Anti-HGenv assay (Boehringer-Mannheim;
(Dille et al 1997).
All donors gave informed consent and ethical approval was obtained for the study.
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5.3 Results
Prevalence of HGV/GBV-C in blood donors. Twenty-three of 1020 (2.25%)
healthy blood donors were positive for HGV/GBV-C RNA in plasma (11 males, mean
age-37.9 years and 12 females, mean age-33.3 years). (Table 5.1). Of the 19 who
returned for further investigation approximately 10 weeks after donation, 18 remained
HGV/GBV-C RNA positive. HGV/GBV-C was detected in 13 of 17 saliva samples
from HGV/GBV-C viraemic donors collected at that time, at levels approximately
three logs lower than found in plasma (geometric means 7.8 x 103 and 7.4 x 106
copies HGV/GBV-C RNA/ml respectively; Table 1). There was a weak correlation
between levels of HGV/GBV-C RNA in plasma and saliva (R=0.442, p = 0.05
[Spearman's rank correlation test]). The donor who had become PCR-negative in
plasma produced a saliva sample that was PCR-positive (4000 copies HGV/GBV-C
RNA/ml).
One year after the original study 11/14 donors who attended for follow-up remained
HGV/GBV-C RNA positive. The three donors who became PCR-negative showed
the lowest virus loads in plasma at time of original donation (p3: 5xl0,pl8:5xl06
and p21: 3 x 104 copies ofHGV/GBV-C RNA/ml; p = 0.017 [Kruskall-Wallis test]).
Clinical assessment of HGV/GBV-C infected blood donors. Two donors (pi3,
p20) of the 18 donors recalled for clinical assessment had a previous history of blood
transfusion. Several donors had undergone ear piercing or tattoos but in
establishments where virus transmission would not be considered likely. None had a
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history of intravenous drug use or sexual contact with an individual at high risk of
parenteral virus infection.
Fourteen of 23 HGV/GBV-C positive donors were clinically examined. None had any
history of jaundice, symptoms or stigmata of chronic liver disease or hepatomegaly.
Five of 18 donors reported various musculoskeletal symptoms, although not of a
consistent pattern and of uncertain relationship to HGV/GBV-C infection. Liver
function tests (LFTs) were carried out for the 19 donors returning after original
donation (Table 5.1). Two donors showed a minimal elevation of alanine
aminotransferase (ALT; 47 and 43 IU/ml [normal range 10-40 IU/ml]). The median
ALT level amongst HGV/GBV-C infected donors was 20 IU/M1, lower than the
median of 32 for a control group of 100 HGV/GBV-C uninfected blood donors (p =
0.015) and a median of 61 for 91 HCV-infected donors (p < 0.0001) (McOmish et al
1993). All other LFT tests (bilirubin, alkaline phosphatase and gamma-glutamyl
transferase) were similarly within the normal range. All measurements in a full blood
count were in the normal range for the 19 donors, apart from mild lymphopoenia in
five.
Two partners donated at the time of the original study and tested negative. Three
partners attended the counselling and follow-up session, and were negative for
HGV/GBV-C RNA in plasma and saliva, and negative for antibody to HGV/GBV-C.
Incidence of HGV/GBV-C infection in blood donors. Archived samples from
previous blood donations of all 23 HGV/GBV-C infected donors were tested by PCR
(Figure. 5.1). All samples from 6 donors (collected from 1986-1994) were PCR-
positive, while the earliest samples from the remaining 17 (1983-1995) were PCR-
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negative. Two donors (plO and pi9) became PCR-positive in 1994 and 1992
respectively, but over the next 1-2 years became transiently PCR-negative and
negative for antibody to E2, before becoming viraemic again at the end of 1996.
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EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF
HGV/GBV-C INFECTED BLOOD DONORS
ALT Previous Plasma Saliva Duration
Donor* Age Sex IU/ml donations copies/mlf copies/mlf infection f
pl2 20 M 25 6 5x 106 <100 1 year
pll 21 F 18 10 5x 108 5 x 104 >2 years
pl5 25 F 18 12 5x 107 5 x 103 1 year
pi 6 26 F 20 17 5 x 108 5 x 104 2 years
p8 27 F 13 6 5x 107 5 x 104 6 years
p!7 27 M 14 >8 years
p6 28 F 18 19 < 100 4x 103 5 years
p9 28 F 15 9 5 x 106 5 x 104 6 years
p5 29 M 38 6 X h—k o
-J 5x 105 10 years
p3 30 M 47 24 5 x 105 4 x 103 2 years
p2 32 F 7 9 years
pl4 32 M 33 7 >5 years
p4 36 F 6 >11 years
pl8 39 M 30 28 5 x 106 5 x 103 6 years
pl9 39 F 27 19 5 x 108 5 x 103 8 years
pl3 40 F 15 12 5x 107 4 years
p22 44 M 42 7 years
p7 45 F 19 11 5x 107 5 x 103 >10 years
Pi 47 M 20 24 5 x 106 5 x 105 7 years
p20 48 M 34 47 5 x 107 5 x 103 9 years
plO 50 M 8 8 5 x 107 5 x 104 3 years
p21 51 M 43 56 3 x 104 <100 9 years
p23 53 F 31 47 5x 106 5 xlO5 9 years
* Donors ranked by age
f HGV/GBV-C virus load in plasma and saliva from donor upon recall
% Approximate duration of HGV/GBV-C infection; time of infection calculated as mid-point
between last PCR negative and first PCR positive donation; in most cases these are minimum
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Figure 5.1. Retrospective testing for HGV/GBV-C-RNA of archived blood donations from 23
blood donors identified as HGV/GBV-C-infected in November-December 1996. 6 donors above
horizontal line are those with persistent infection throughout the observation period. •,
HGV/GBV-C PCR-positive; x, PCR-negative.
A total of 17 blood donors became infected with HGV/GBV-C over a mean
observation period of 9.7 years. The number of susceptible blood donors investigated
was 1046 (excluding the persistently viraemic donors during the observation period).
Therefore, an approximate calculation of the incidence of HGV/GBV-C infection
would be 0.17% per year.
A technical explanation for the large number of HGV/GBV-C negative samples
collected before 1990 is that HGV/GBV-C RNA sequences had degraded upon long-
term storage, although positive samples from individuals (p4 and p7) were recorded
before this date. Although this hypothesis was not experimentally tested, it was
possible to re-calculate the incidence of HGV/GBV-C infection using shorter time
intervals. Using only the results from 1990 onwards, and assuming that HGV/GBV-C
infection occurred at the mid-point between the last PCR negative and first PCR
positive sample, a total of 13 blood donors became infected over a mean interval of
6.2 years, producing an annualised incidence of 0.20% per year). Similarly, 8 became
positive from 1992 onwards (mean observation period 4.5 years, incidence 0.17% per
year). The similarity in these estimates suggests that degradation of HGV/GBV-C
RNA storage did not affect the calculation of incidence.
A final qualification in interpreting the incidence calculation arises from the
assumption that all donors (other than those who were persistently infected) are
susceptible to HGV/GBV-C infection. The proportion of donors with past resolved
infection with HGV/GBV-C (and who may be anti-E2 positive) was not determined in
this study, although other studies of similar donor populations have documented
frequencies of 7.4%-16% (Lou et al 1997, Tacke et al 1997, Feucht et al 1997). The
estimates for incidence presented above apply to the blood donor population as a
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Prevalence and incidence of HGV/GBV-C infection. In this study we have
demonstrated that 23/1020 (2.25%) of healthy non-remunerated blood donors had
plasma samples positive for HGV/GBV-C RNA by RT PCR. This frequency lies
within the range reported for comparable non-remunerated blood donor populations
in other countries such as Germany (1.3%-1.9%, (Feucht et al 1997, Rith et al 1997)),
France (4.2%, (Loiseau et al 1997), USA (1.7%, (Linnen et al 1996)), Australia (4%,
(Moaven et al 1996)) and Japan (0.5%-1.2%, (Yoshikawa et al 1997, Orita et al
1996)). The male-female ratio of HGV/GBV-C infected donors was 11:12, different
from the 3:1 ratio observed in amongst blood donors infected with HCV in Scotland
(McOmish et al 1993) or elsewhere. The high prevalence ofHGV/GBV-C infection,
the different male/female ratio, and the absence of significant disclosed parenteral risk
factor for infection in the HGV/GBV-C infected donors strongly suggests other
routes of transmission.
Amongst other proposed routes of transmission of HGV/GBV-C, evidence for
transmission by sexual contact includes the finding of high prevalence of infection in
individuals with sexually transmitted disease, or with other evidence of sexual
exposure with multiple partners (Stark et al 1996, Kao et al 1997, Wu et al 1997,
Scallan et al 1998). Against this hypothesis is the absence of detectable transmission
of HGV/GBV-C (either by PCR or serology) to the sexual partners of 5 infected
donors. Mother to child transmission has been documented by the frequent detection
ofHGV/GBV-C viraemia (20-70%) in children born from infected mothers (Moaven
et al 1996, Viazov et al 1997, Feucht et al 1996, Fischler et al 1997), and the genetic
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identity of HGV/GBV-C maternal and infant strains (Viazov et al 1997). However,
the observation of de novo infection in at least 17 of the 23 HGV/GBV-C infected
blood donors in the current study indicates the acquisition of infection occurred
predominantly in adulthood.
The frequent finding of HGV/GBV-C positive samples amongst archived donations
from the infected donors indicates that infection may persist for several years (at least
10 years in p4). The results of this retrospective study are consistent with the finding
of persistent infection of at least 2 years amongst 4 of 5 Australian blood donors
(Moaven et al 1996), and the documented prolonged infection in varying proportions
of individuals infected with HGV/GBV-C through blood transfusion or treatment with
blood products (Roth et al 1997, Hwang et al 1997, Lefrere et al 1997, Hanley et al
1998).
A surprising finding that arose from the retrospective study was the relatively high
incidence of HGV/GBV-C infection. The calculated rate (170-200 infections per
100,000 person years) contrasts strongly with rates of acquisition ofHCV (1.8-10 per
100,000, (Prati et al 1997, Riggert et al 1996, Saski et al 1996, Itoh et al 1996, Whyte
et al 1997)), HIV (1.3 - 4.0 per 100,000, (Itoh et al 1996, Whyte et al 1997, Remis et
al 1997)) and HBV (1.7 - 4.0, (Itoh et al 1996, Whyte et al 1997)) in similar non-
remunerated blood donor populations in Europe, USA, Japan and Australia. If in the
future, donations were to be screened for HGV/GBV-C RNA by PCR, the number of
new infections detected would place severe constraints on the size of the pool used.
For example, even if all persistently infected donors were excluded, new infections
with HGV/GBV-C over a mean donation interval of 6 months would lead to
165
contamination of 50% of pools containing 500 component donations, and 10% of
pools containing 100 components.
Clinical assessment of HGV/GBV-C infected donors. The asymptomatic nature of
HGV/GBV-C was directly demonstrated by our clinical examination of the infected
donors. Two donors showed minimal elevation of ALT levels, but the mean level (20
IU/ml) and all other liver function tests were in the normal range. No subject had a
previous history of acute hepatitis or jaundice. No donor had any abnormality on
clinical examination, other than non-specific musculoskeletal symptoms in 5
individuals. However there was no consistent pattern ofjoint involvement, and larger
studies would be required to make a more substantive link.
These findings are consistent with the absence of clinically or biochemically apparent
liver disease in those infected by blood transfusion (Alter et al 1997b, Wang et al
1996, Yashina et al 1997). For example, of 79 cases ofPTH, only three patients were
infected with HGV/GBV-C alone (Alter et al 1997b), all had mild, asymptomatic
hepatitis, and the absence of any correlation between ALT elevation and detection of
HGV/GBV-C by PCR suggests other causes for the observed hepatitis. In another
study only 1/48 patients with acute non A-E hepatitis had detectable HGV/GBV-C
RNA levels by RT PCR (Nakatsuji et al 1996).
Although early reports indicated a significantly higher frequency of GBV-C/HGV
infection in patients with non A-non E hepatitis (Linnen et al 1996, Fioradalisi et al
1996, Colombatto et al 1996), later studies have largely discounted this association
(Feucht et al 1997, Moaven et al 1996, Matsumura et al 1997, Alter et al 1997a,
Sarrazin et al 1997, Sugai et al 1997, Tanaka et al 1997, Thomas et al 1997, Zhang et
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al 1997, Ross et al 1997). In patients with dual infection with HGV/GBV-C and
HCV, HGV/GBV-C had no effect on clinical outcome and ALT levels correlated with
HCV rather than HGV/GBV-C levels. In the 16/519 HGV/GBV-C positive
haemodialysis patients none had raised ALT levels despite having documented
persistent infection for up to 16 years (Masuko et al 1996). Viruses that are able to
establish persistent infection often produce chronic disease, but there are no
prospective studies that document progression of HGV/GBV-C to cirrhosis,
hepatocellular carcinoma or decompensated liver disease, in marked contrast with
chronic HCV infection (Seeff et al 1992).
A difficulty encountered in investigating the HGV/GBV-C infected donors in the
current study arose from the current lack of information about the tropism and likely
disease associations of GBV-C/HGV in vivo. Although HGV/GBV-C RNA can be
detected in the liver (Saito et al 1997), there is little evidence for its replication there
(Laskus et al 1997, Kudo et al 1997, Mellor et al 1998). Thirteen of seventeen of our
HGV/GBV-C positive donors showed relatively high levels ofHGV/GBV-C RNA in
saliva, and a mean ratio to levels detected in plasma of approximately 1:1000. The
frequency of detection and ratio to levels detected in plasma contrasts with that
documented for HCV, and suggests that replication of HGV/GBV-C in the
respiratory or gastrointestinal tracts may occur. None of them had any history of
respiratory symptoms or disease, although its secretion into saliva may represent a
route of transmission, as documented for HCMV and other herpes viruses.
In conclusion this study demonstrates that HGV/GBV-C infection is common
amongst our donor population but is not associated with significant hepatic disease or
symptoms. We have not been able to identify a risk factor for infection in the majority
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of HGV-positive donors. HGV/GBV-C RNA was present in the plasma in the
majority of subjects for several years and was likely to have been transfused in a large
number of blood components. These findings will enable recipients of HGV/GBV-C
positive blood to be identified and the clinical sequelae investigated. In the interim, in
the absence of clinicopathological data suggesting significant morbidity in




DISCUSSION AND SUGGESTIONS FOR FUTURE
WORK
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Hepatitis C virus has dominated the practice of clinical hepatology since its discovery
in 1989. It is common, predominantly transmitted parenterally and can be silent for
many years only becoming apparent when clinically significant complications occur. It
is the most common cause of post transfusion hepatitis worldwide and is now a
leading cause of liver disease requiring OLT.
Current treatment strategies are still not 100% effective and an effective vaccine is not
imminently available. Disease progression is not uniform. Establishing those factors
associated with accelerated progression or a more benign course of disease is
therefore of clinical relevance.
This thesis examined some of the factors important in progression of disease in this
cohort of patients. In chapters 2 and 3 various factors were examined. In keeping
with the majority of regions in the United Kingdom the most common route of
transmission of infection was through intravenous drug use. This is reflected in the
low mean age at infection. In this cohort route of infection did not appear to play a
significant role in progression to cirrhosis. There are conflicting results with some
studies demonstrating that infection through blood transfusion is associated with more
severe histological findings. (Gordon et al 1997). More recent work has concluded
that route of infection does not influence progression to cirrhosis.
In interpreting these results it must be recognised that the patients studied may not
reflect the general HCV population. This may occur as a result of particular referral
patterns to a tertiary referral centre. In chapter 4 route of infection did not have any
significant association with any domain of QOL. This was unexpected given the
perceived chaotic lifestyle and other comorbidity associated with intravenous drug
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use. Selection bias may account for this finding. Patients attending clinics may be
better motivated and are less likely to be currently abusing drugs.
Alcohol consumption was strongly associated with increased fibrosis and
progression to cirrhosis. This has been previously reported by many authors (Poynard
et al 1997, Wiley et al 1998) and discussed in more detail in chapter 2. When QOL
was measured in chapter 4 alcohol intake had no significant effect on any of the QOL
domains. This implies therefore that although excess alcohol consumption is
associated with a more rapid progression of disease it is not associated with a
diminished QOL.
ALT values in chapter 2 had no apparent effect on inflammation or fibrosis. It has
now been conclusively shown that ALT levels are a poor indicator of hepatic
histology. (Healey et al 1995, Naito et al 1994, Bruno et al 1994). However ALT
values have been shown to be associated with progression of disease. Raised ALT has
now been reported to be associated with a more rapidly progressive disease (Ghany et
al 2000, Marcellin 2002) and normal ALT is associated with a slower rate of
progression to cirrhosis ( Freeman et al 2001). Because the biopsies in the cohort in
chapter 2 were not done sequentially, rate of progression to cirrhosis related to level
ofALT cannot be assessed in this population.
When HLA status was analysed in chapter 3 HLA DR6 was associated with
persistently normal transaminases and HLA B7 and DR7 with abnormal
transaminases. This may therefore suggest that DR6 is associated with a slower rate
of progression to cirrhosis and B7 and DR7 are associated with a more rapid
progression to cirrhosis given the studies reported above. It would require histological
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confirmation to be absolutely certain. When ALT values were examined in relation to
QOL in chapter 4 no significant relationship was found.
Age at time of infection was also shown in chapter 2 to be associated with a more
rapid progression to cirrhosis. The reasons for this are not entirely clear but may be
related to impaired immunity in older people. When QOL was examined in chapter 4
those aged over 40 years old at time of infection had worse scores in physical function
and vitality compared to younger patients. What needs to be ascertained is the reason
for accelerated progression in older people as this may help to explain the impaired
QOL in these patients.
Male sex was also associated with an increased degree of liver fibrosis. Other authors
have reported similar findings. (Poynard et al 1997).
In chapter 3 the role of HLA status in progression to cirrhosis was examined. HLA
B35 was found to protect against the development of cirrhosis. HLA is a critical
genetic factor that determines individual variations of the immune response to
antigens. As previously discussed in chapter 1 The T cell mediated response is
important in the development of hepatocellular damage and persistence of infection
and it might be speculated that HLA type affects the immune response in certain
patients with HCV infection thus resulting in more rapidly progressive disease.
One of the major findings in this study was that HLA DR5 appeared to protect against
the development of chronic disease as none of our HCV infected patients in the HLA
study had the DR5 allele.This concurs with other studies. (Zavaglia et al 1996, Thursz
et al 1996). A further study found that the presence of DR5 was associated with a
benign course of liver disease in Caucasians. (Peano et al 1994). The mechanism by
which the HLA class II molecules confer protection against or susceptibility to
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chronic hepatitis C is probably related to the function of these molecules in the
immune responses and their differing ability to bind and present viral peptides.
However the evidence for importance of HLA antigens in viral hepatitis C is
conflicting and various other studies have found relationships between other HLA
types and protection from and susceptibility to progressive disease. (Czaja et al 1995,
Zavaglia et al 1998, Kuzushita et al 1996, Verdon et al 1994, Vitte et al 1995).
Serotyping has now largely been superceded by DNA typing which is known to be
superior e.g. genomic typing of the gene coding for HLA DR11 at serological level
may yield up to 16 alleles in different ethnic groups. (Zavaglia et al 1998). Ideally
DNA typing would have been used in this study for the reasons discissed in chapter
3. A further source of potential bias is the relatively small number of patients studied
and it would be worthwhile repeating the study using DNA typing and a significantly
larger study group.
In chapter 4 quality of life in HCV was examined. There are many studies now
documenting the progressive nature of chronic HCV infection. However there have
been fewer studies examining the impact of this chronic disease on patients well being
and QOL. Part of the problem is developing appropriate instruments to measure any
impairment present and determining whether the instrument used are reliable and valid
and therefore measure what you are aiming to measure. This study clearly
demonstrated, using several reliable and well-validated instruments, that QOL is
impaired across several physical and mental domains in patients with chronic HCV
infection. The exact reasons for this are less clear. It has been shown in several studies
that QOL improves after treatment. Ware et al 1999, Bonkovosky et al 1999).
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In addition the diagnosis of inflammation and/or fibrosis on liver biopsy has previously
been used as an indication ofwho to treat. In chapter 4 it was demonstrated that the
presence of inflammation on biopsy does not correlate with QOL. Part of the aim of
treatment is obviously to improve symptoms and this implies that the use of objective
markers alone not sufficient. Also consideration must be given to the possibilty of
treatment for patients who may not have histologically progressive or severe disease
but who have debilitating symptoms and impaired QOL. Should people be treated on
the basis of symptoms and QOL rather than on histological, virological and
biochemical markers?
In chapter 5 a novel flavivirus HGV was investigated. When HCV was identified it
became apparent that it did not account for all the cases of PTH and community
acquired non A, non-B hepatitis. The remaining group has been termed non A-E
hepatitis and is believed to have a viral aetiology. Linnen et al cloned HGV from the
serum of a patients with non-A non-B hepatitis (Linnen et al 1996) whilst Leary et al
identified the isolate GBV-C. They isolated three viral agents from the serum of a
tamarin inoculated with serum from a surgeon who had contracted hepatitis. GBV-C
was thought to be the likely viral hepatitis candidate in humans. (Leary et al 1996).
Sequence comparisons of the two viruses revealed that they were isolates of the same
viruses and had similarities to other members if the flaviviridae such as HCV. Was this
virus then responsible for the undiagnosed cases of non A-E hepatitis? Early studies
suggested that HGV RNA was present in 14% of patients with non A-E hepatitis
however similar numbers of patients with acute hepatitis A infection also had HGV-
RNA in their serum. (Karayiannis et al 1997b). Prospective studies have shown that
HGV can be transmitted by blood transfusion. Other studies have documented high
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prevalence of HGV-RNA in people with frequent parenteral exposure including
IVDU, haemodialysis patients and patients with haemophilia. (Hadziyannis et al 1995,
Aikawa et al 1996, Masuko et al 1996, Jarvis et al 1996). Mother to infant and sexual
transmission have also been demonstrated. (Feucht 1996, Scallan et al 1998). The role
of HGV in acute fulminant hepatitis is more controversial with initial reports
suggesting a direct link (Yoshiba et al 1995) however subsequent studies would
suggest there is no significant role for HGV in fulminant hepatitis. (Haydon et al
1997, Sallie et al 1996, Kuroki et al 1996). On this background the study in chapter 5
aimed to determine the prevalence of HGV in a population of blood donors to
determine the natural history of infection and assess its clinical significance. A
prevalence rate of 2.25% was found. This is in keeping with other studies of blood
donor prevalence in Northern Europe. HGV-RNA was found to be persistent in
plasma over time and HGV-RNA was found in the saliva in many of the donors
positive for HGV-RNA. The majority of donors had no clinical or biochemical
evidence of liver disease. There was no evidence of sexual transmission in this small
cohort of infected donors. If all donors with HGV-RNA were to be excluded from
donating this would result in a significant reduction in the number of donated blood
units able to be used. In this climate of falling blood donations this would potentially
have serious implications. On balance with all the evidence available pointing to the
fact that HGV does not appear to cause significant liver disease there seems little
justification in routinely testing all blood donors for HGV-RNA.
It is still important to determine whether HGV is a hepatotropic virus or whether it is
a virus with other tissue tropism. Does HGV cause any clinically significant disease?
It is also important to develop an appropriate serological test to identify those with
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previous infection and without current viraemia as this would aid in studies of the
long-term implications of this seemingly innocuous virus. It does however imply that
there is another virus, not yet discovered, that is the cause for the remaining cases of
non-A-E hepatitis.
Suggestions for future work
There are now more successful treatment modalities available for patients with
chronic HCV infection. Novel ways of successfully treating those who do not respond
to standard combination therapy with ribavirin and interferon-alpha are required
Further studies examining different dose and duration regimens are necessary as well
as examining the efficacy of other agents either as combination therapy or as part of a
triple therapy regime.
In HLA studies the gold standard test is DNA typing. We need to perform larger
studies using this technique in our population and also assessing HLA status with
more accurate markers of liver inflammation and fibrosis.
In Quality of Life there is much to be learned. The mechanisms of impaired QOL need
to be determined as they are poorly understood. More studies need to be carried out
examining the effect of treatment on QOL and to assess whether the improvement,
which has been documented in the initial studies done, is maintained over significant
periods of time e.g. 5 years.
Finally with HGV many of the studies have now been completed. It is important to
further investigate the effects of the HGV elsewhere on the body and any long-term
effects as this would potentially have significant implications for blood donor
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screening. The search for the new virus for non-A-E continues and although other
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1) DECOMPENSATED LIVER DISEASE
2) JAUNDICE





6) OTHER RELEVANT SIGNS




SF - 25 HEALTH SURVEY date, id / rno
Instructions : This survey asks for your views about your health. This information will
help keep track of how you feel and how well you are able to do your usual activities.
Answer every question by marking the answer as indicated. If you are unsure about
how to ansv/er a question, please give the best answer you can.







2 Comoared to one year aoo how would you rate your health now ?
(circle one)
Much better now than one year ago 1
Somewhat better now than one year ago 2
About the same as one year ago 3
Somewhat worse now than one year ago 4
Much worse now than one year ago 5
3 i he following questions are about activities you might do during a typical day.
Does your heaith now limit vou in these activities. If so, how much ?










Vigorous activities, such as running, lifting
heavy objects, participating in strenuous
SDorts
2 3
Moderate activities, such as moving a
table, pushing a vacuum cleaner, bowling or
Dlavina oolf
1 2 3
Lifting or carrying groceries 1 2 3 ■:
Climbing several flights of stairs 1 2 3
Climbing one flight of stairs 2 3
Bending, Kneeling or Stooping 1 2 3
Walking more than one mile 1 2 3
Walking half a rniia 2 3
Walking one hundred yards 1 2 oO
Bathing or dressing yourself 1 2 3
4 During the past 4 weeks, have you had any of the following problems with your
work or other regular daily activities as a result of your physical health ?
(circle one number on each line)
YES NO
Cut down on the amount of time you spent on work or
other activities
1 2
Accomplished less than you would like 1 2
Were limited in the kind of work or other activities 1 2
Had difficulty performing the work or other activities
(for examDle. it took extra effort)
1 2
5 During the oast 4 weeks, have you had any of the following problems with your
work or other regular daily activities as a result of anv emotional problems
(such as feeling depressed or anxious) ?
(circle one number on each line)
YES | NO
Cut down on the amount of time you spent on work
or other activities
1 2
Accomplished less than you would like 1 2
Didn't do work or other activities as carefully as usual 1 2
6 During the past 4 weeks, to what extent has your physial health or emotional
problems interfered with your normal social activities with family, friends,
neighbours, or groups ?
(circle one)
Not at all 1
Slightly 2
Moderately 3
Quite a bit 4
Extremely -.5








8 During the pest 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework) ?
(circle one)
Not at all 1
A little bit 2
Moderately 3
Quite a bit 4
Extremely 5
These questions are about how you feel and how things have been with you
during the oast 4 weeks. For each question, please give the one answer that
comes closest to the way you have been feeling.
How much of the time during the oast 4 weeks.















Did ycu feel full of life ? 1 2 3 4 5 6
Have you been a very nervous person ? 1 2 3 4 5 6
Have you feit so down in the dumps that
nothina could cheer vou uo ?
1 2 3 4 5 6
have you felt calm and peaceful ? 1 2 3 4 5 6
Did you have a lot of energy ? 1 2 3 4 5 6
Have you felt downhearted and lew ? 1 2 3 4 5 .= S
Did you feel worn out ? 1 2 3 4 5 6
Have you been a happy person 1 2 3 4 5 6
Did you feel tired ? 1 2 3 4 5 S
1 0 During the oast 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with friends,
relatives, etc) ?
(circle one)
All of the time 1
Most of the time v 2
Some of the time 3
A little of the time 4
None of the time 5
1 1 How TRUE or FALSE is each of the following statements for you ?











I seem to get ill more easily than
other Deoole
1 2 3 4 5
I am as healthy as anybody I know 1 2 3 4 5
I expect my health to get worse r 2 3 4 5
My heaith is excellent 1 2 3 4 5








This questionnaire asks fiow you feel about your quality of life, health, and other areas
of your life. Please answer all the questions. If you are unsure about which response to give to
a question, please choose the one that appears most appropriate. This can often be your first
response.
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you
think about your life in the last two weeks.
For example, thinking about the last two weeks, a question might ask:
How much do you worry about your health?
Not at all A little A moderate
amount
3
Very much An extreme
amount
5
You should circle the number that best fits how much you have worried about your
health over the last two weeks. So you would circle the number 4 if you worried about your health
"Very much", or circle number 1 if you have worried "Not at all" about your health. Please read
each question, assess your feelings, and circle the number on the scale for each question that gives
the best answer for you.
Thank you for your help
WHOQOL-lOO FOR FIELD TRIALS
MNH/PSF/95.1 .D.Rev. 1
Pag© 3
The following questions ask about how much you have experienced certain things
in the last two weeks, for example, positive feelings such as happiness or
contentment. If you have experienced these things an extreme amount circle the
number next to "An extreme amount". If you have not experienced these things at
all, circle the number next to "Not at all". You should circle one of the numbers in
between if you wish to indicate your answer lies somewhere between "Not at all" and
"Extremely". Questions refer to the last two weeks.
























































F3.2 (F4.1.3) Do you have any difficulu'es with sleeping?





























The numbers in brackets refer to the number of the question in the pilot question pool. National versions must be constructed
using that same question taken from national version of the pilot questionnaire.
r
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.4(F28.2.3)How much do difficulties with transport restrict your life?
Not at all
1
























These questions were inappropriately given a capacity response scale in the pilot version. They are to be given an intensity
scale in the WHOQOL-IOO.
WHOQOL-lOO FOR FIELD TRIALS
MNH/PSF/95.1 .D.Rev. 1
Page 7
The following questions ask about how completely you experience or were able to
do certain things in the last two weeks, for example activities of daily living such as
washing, dressing or eating. If you have been able to do these things completely,
circle the number next to "Completely". If you have not been able to do these things
at all, circle the number next to "Not at all". You should circle one of the numbers
in between if you wish to indicate your answer lies somewhere between "Not at all"
and "Completely". Questions refer to the last two weeks.







F7.1(F9.1.2) Are you able to accept your bodily appearance?
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ie following questions ask you to say how satisfied, happy or good you have felt
out various aspects of your life over the last two weeks . For example, about your
"nily life or the energy that you have. Decide how satisfied or dissatisfied you are
th each aspect of your life and circle the number that best fits how you feel about
s. Questions refer to the last two weeks.
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The following questions refer to how often you have felt or experienced certain
things, for example the support of your family or friends or negative experiences such
as feeling unsafe. If you have not experienced these things at all in the last two
weeks, circle the number next to the response "never". If you have experienced these
things, decide how often and circle the appropriate number. So for example if you
have experienced pain all the time in the last two weeks circle the number next to
"Always". Questions refer to the last two weeks.
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The following questions refer to any "work" that you do. Work here means any
major activity that you do. This includes voluntary work, studying full-time,
taking care of the home, taking care of children, paid work or unpaid work. So
work, as it is used here, means the activities you feel take up a major part of your
time and energy. Questions refer to the last two weeks.
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The next few questions ask about how well you were able to move around, in
the last two weeks. This refers to your physical ability to move your body in such
a way as to allow you to move about and do the things you would like to do, as
well as the things that you need to do.
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The following few questions are concerned with your personal beliefs, and how
these affect your quality of life. These questions refer to religion, spirituality and
any other beliefs you may hold. Once again these questions refer to the last two
weeks.













































vTiat is your gender?
Male
Female
/hat is your date of birth?
J
DAY / MONTH / YEAR





hat is your marital status?


























Broken or fractured bone
Chronic nervous or emotional problems
Chronic foot trouble (bunions, ingrowing toenails)




If yes, what is your diagnosis?
This question wis originaUy ir. the body of rated Questions in the pilot questionnaire.
Read each item and place a tick in the box opposite the reply which comes closest
to how you have been feeling in the past week.
Don't take too long over your replies: your immediate reaction to each item will
probably be more accurate than a long thought-out response.
I feel tense or 'wound up':
Most of the time
A lot of the time
Time to time, Occasionally
Not at all
I still enjoy the things I used to enjoy:
Definitely as much
Not quite so much
Only a little
Hardly at all
I get a sort of frightened feeling as if
something awful is about to happen:
Very definitely and quite badly
Yes, but not too badly
A little, but it doesn't worry me
Not at all
I can laugh and see the funny side of
things:
As much as I always could
Not quite so much now
Definitely not so much now
Not at ail
Worrying thoughts go through my
nind:
A great deal cf the time
A lot of the time






Most of the time





I feel as if I am slowed down:




I get a sort of frightened feeling like





[ have lost interest in my appearance:
Definitely
I don't take so much care as I should....
I may not take quite as much care
I take just as much care as ever
I feel restless as if I have to be on the
move:
Very much indeed
Quite a lot ..„
Not very much
Not at all
I look forward with enjoyment to things:
As much as ever I did
Rather less than fused to
Definitely less than I used to
Hardly at all












Please circle the appropriate item to indicate how much you have been bothered by
the following during the last month:
Spells of confusior NOT AT ALL A LITTLE SOMEWHAT QUITE A LOT VERY MUCH
Thoughts getting
mixed up
NOT AT ALL A LITTLE
/>
SOMEWHAT QUITE A LOT VERY MUCH
Poor
concentration





NOT AT ALL A LITTLE SOMEWHAT QUITE A LOT VERY MUCH
Poor memory for
recent events




NOT AT ALL A LITTLE SOMEWHAT QUITE A LOT VERY MUCH
Thoughts are slow NOT AT ALL A LITTLE SOMEWHAT QUITE A LOT VERY MUCH
Muzzy head NOT AT ALL A LITTLE SOMEWHAT QUITE A LOT VERY MUCH
Can't find the right
words




Prevalence, Incidence, and Clinical Characteristics of Hepatitis G Virus/GB
Virus C Infection in Scottish Blood Donors
C. S. Blair, F. Davidson, C. Lycett, D. M. McDonald,
G. H. Haydon, P. L. Yap, P. C. Hayes, P. Simmonds,
and J. Gillon
Departments of Medicine and ofMedical Microbiology, University of
Edinburgh, Royal Infimtary of Edinburgh, and Southeast Scotland
Blood Transfusion Service, Edinburgh, United Kingdom
The prevalence, incidence, clinical features, and natural history of hepatitis G virus (HGV)
or GB virus C (GBV-C) were investigated in a non-remunerated blood donor population
to determine its clinical significance and its impact on blood safety. Of 1020 regular blood
donors, 23 (2.25%) were positive for plasma HGV/GBV-C RNA. Alanine aminotransferase
levels were lower than in uninfected donors (median, 20 IU/mL; 32 IU/mL in controls; P =
.015). Clinical examination produced no other evidence for hepatitis or for shared nonhepadc
diseases. Fifteen of 17 donors excreted HGV/GBV-C in saliva (mean level, 8 X 103 copies of
RNA/mL). Testing of previous donations indicated an incidence of 170-200 new infections
with HGV/GBV-C per 100,000 donor-years. The absence of further clinicopathologic data
and the limitations of current polymerase chain reaction-based methods for screening suggests
that it is neither necessary nor practical to commence screening.
Hepatitis C virus (HCV) has been identified as the principal
cause of posttransfusion hepatitis, while the development of
serologic tests for blood donor screening has led to a dramatic
fall in its incidence. However, in 10% of occurrences of post¬
transfusion hepatitis and 20% of community-acquired hepatitis,
no etiologic agent has been identified. GB virus C (GBV-C) [1]
or hepatitis G virus (HGV) [2] has been proposed as the eti¬
ologic agent of these residual cases. In this study, we aimed to
determine the prevalence of HGV/GBV-C in a large sample of
the Scottish donor population and the natural history of this
population's infection with the virus and to assess the clinical
significance and possible risk factors for transmission of infec¬
tion in HGV/GBV-C-positive donors.
Subjects and Methods
Subjects. From October 1996 until December 1996, 1020
blood samples were collected from volunteer, consecutive, reg¬
ular blood donors attending the Edinburgh and Southeast Scotland
Blood Transfusion Service center. Consent to participate in the
screening program was obtained from 1020 (97%) of 1052 donors
interviewed. All subjects were seronegative for human immuno-
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UK, September 1997.
Consent for HGV/GBV-C testing, recall, and examination was obtained
from all blood donors who participated in the study. The study was ap¬
proved by the Lothian Research Ethics Committee.
Grant support: Scottish National Blood Transfusion Service.
Reprints or correspondence: Dr. Carol Blair, Department of Medicine
(R1E), University of Edinburgh, Royal Infirmary, Lauriston Place, Edin¬
burgh, EH3 9YW, United Kingdom.
The Journal of Infectious Diseases 1998; 178:1779-82
© 1998 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/98/7806-0032$02.00
deficiency virus (HIV), hepatitis B virus (HBV), and HCV. All
HGV/GBV-C-positive donors were contacted and invited to attend
for counseling and further investigation. At their initial consulta¬
tion, repeat sampling for plasma HGV/GBV-C RNA and alanine
aminotransferase (ALT) measurement was undertaken, and a his¬
tory of risk behavior was sought. In addition, a sample of saliva
was collected for testing for HGV/GBV-C RNA. All positive do¬
nors were referred to a single hepatologist for clinical evaluation.
Detection of HGVIGBV-C RNA and antibody in plasma. De¬
tection and quantitation of HGV/GBV-C was done as previously
described [3] on RNA extracted from 100 ph of EDTA-
anticoagulated plasma or citrated plasma from blood donors that
was combined into pools of 10. Positive pools were subdivided into
component donations and retested. Initial screening identified 23
positive pools, which led to the identification of one positive com¬
ponent donation in each. RNA was also extracted from 100-pL
volumes of saliva samples as described for plasma samples. IgG
antibodies to GBV-C/HGV E2 antigen were detected by assay
(PLATE Anti-HGenv; Boehringer Mannheim, Mannheim,
Germany).
Results
Prevalence of HGV/GBV-C in blood donors. Twenty-three
(2.25%) of 1020 healthy blood donors were positive for HGV/
GBV-C RNA in plasma (11 men [mean age, 37.9 years] and
12 women [mean age, 33.3 years]; table 1). Nineteen returned
for further investigation -10 weeks after donation, and 18 re¬
mained HGV/GBV-C RNA-positive. HGV/GBV-C was de¬
tected in 13 of 17 saliva samples from HGV/GBV-C-viremic
donors collected at that time. Levels in saliva were -3 log
lower than found in plasma (geometric means, 7.8 X 103 and
7.4 X 106 copies of HGV/GBV-C RNA/mL, respectively; table
1), but levels showed a weak correlation (R = .442, P = .05
[Spearman's rank correlation test]). The donor who had become
1780 Concise Communications JID 1998;178 (December)
















pl2 20 M 25 6 5X 10" <100 1
pll 21 F 18 10 5x 10s 5x 104 >2
PI5 25 F 18 12 5X 10' 5X 103 1
p 16 26 F 20 17 5x 10' 5X 10" 2
p8 27 F 13 6 5x 10' 5 X I04 6
P17 27 M 14 >8
p6 28 F 18 19 <100 4X 10' 5
p9 28 F 15 9 5X 10s 5X 10" 6
P5 29 M 38 6 5X 107 5X 105 10
P3 30 M 47 24 5X 10s 4X 101 2
P2 32 F 7 9
pl4 32 M 33 7 >5
p4 36 F 6 >11
p 18 39 M 30 28 5X 106 5 X 103 6
p 19 39 F 27 19 5X 10s 5X 103 8
P13 40 F 15 12 5X 10' 4
p22 44 M 42 7
P7 45 F 19 11 5X 10' 5X 103 >10
Pi 47 M 20 24 5X 10s 5X 103 7
p20 48 M 34 47 5 X 10' 5X 103 9
plO 50 M 8 8 5X 10' 5X 104 3
P21 51 M 43 56 3X 10" <100 9
p23 53 F 31 47 5X 10' 5X 10s 9
NOTE. ALT, alanine aminotransferase.
u
Donors are ranked by age.
b HGV/GBV-C load in plasma and saliva from donor on recall.
c
Approximate duration of HGV/GBV-C infection; time of infection is cal¬
culated as midpoint between last polymerase chain reaction-negative and first
polymerase chain reaction-positive donation; in most cases these are minimum
estimates, as donors have been followed prospectively for at longest 1 year (figure
I)-
polymerase chain reaction (PCR)-negative in plasma produced
a saliva sample that was PCR-positive (4000 copies of HGV/
GBV-C RNA/mL).
One year after the original study, 11 of 14 donors who at¬
tended for follow-up remained HGV/GBV-C RNA-positive.
The 3 donors who became PCR-negative showed the lowest
virus loads in plasma at time of original donation (p3,
5 X 105; pi8, 5 X 10"; and p21, 3 X 104 copies of HGV/GBV-
C RNA/mL; P = .017 [Kruskal-Wallis test]). The sample from
p3 was reactive in the Boehringer anti-E2 ELISA (optical den¬
sity [OD] of 1.6), but those from pi8 and p21 were negative
(ODs of 0.036 and 0.073, respectively).
Clinical assessment of HGVIGBV-C-infected blood donors.
Two donors (pi3, p20) of the 18 donors recalled for clinical
assessment had a history of blood transfusion. Several donors
had undergone ear piercing or tattoos but in establishments
where virus transmission would not be considered likely. None
had a history of intravenous drug use or sexual contact with
a person at high risk of parenteral virus infection.
Fourteen of 23 HGV/GBV-C-positive donors were clinically
examined. None had any history of jaundice or symptoms or
stigmata of chronic liver disease or hepatomegaly. Five of 18
donors reported various musculoskeletal symptoms, although
not of a consistent pattern and of uncertain relationship to
HGV/GBV-C infection. Liver function tests were carried out
for the 19 donors returning after original donation (table 1).
Two donors showed a minimal elevation in ALT level (47 and
43 IU/mL [normal range, 10-40 IU/mL]). The median ALT
level among HGV/GBV-C-infected donors was 20 IU/mL,
lower than the median of 32 for a control group of 100 HGV/
GBV-C-uninfected blood donors (P = .015) and a median of
61 for 91 HCV-infected donors (P< .001) [4], All other liver
function tests (bilirubin, alkaline phosphatase, and y glutamyl
transferase) were similarly within the normal range. All mea¬
surements in a full blood count were in the normal range for
the 19 donors, apart from mild lymphopenia in 5.
Donations from 2 partners of HGV/GBV-C-infected donors
who donated at the time of the original study were HGV/GBV-
C PCR-negative. Three partners who attended the counseling
and follow-up session were negative for HGV/GBV-C RNA in
plasma and saliva and negative for antibody to HGV/GBV-C.
Incidence of HGVIGBV-C infection in blood donors. Ar¬
chived samples from previous blood donations of all 23 HGV/
GBV-C-infected donors were tested by PCR (figure 1). All
samples from 6 donors (collected during 1986-1994) were PCR-
positive, while the earliest samples from the remaining 17
(1983-1995) were PCR-negative. Two donors (plO and pl9)
became PCR-positive in 1994 and 1992, respectively, but over
the next 1-2 years became transiently PCR-negative and neg¬
ative for antibody to E2, before becoming viremic again at the
end of 1996. A total of 17 blood donors became infected with
HGV/GBV-C over a mean observation period of 9.7 years. The
number of susceptible blood donors investigated was 1046 (ex¬
cluding the persistently viremic donors during the observation
period), allowing an approximate calculation of the incidence
of HGV/GBV-C infection of 0.17% per year.
One explanation for the large number of HGV/GBV-
C-negative samples collected before 1990 is that HGV/GBV-
C RNA sequences had degraded on long-term storage. We
recalculated the incidence of HGV/GBV-C infection using
shorter time intervals. When we used only the results from
1990 onwards, a total of 13 blood donors became infected
over a mean interval of 6.2 years (incidence, 0.20% per year).
Similarly, 8 became positive from 1992 onwards (mean obser¬
vation period, 4.5 years; incidence, 0.17% per year). The sim¬
ilarity in these estimates suggests that degradation of HGV/
GBV-C RNA during storage did not affect the calculation of
incidence.
Discussion
In this study, we have demonstrated that 23 (2.25%) of 1020
healthy non-remunerated blood donors had plasma samples
positive for HGV/GBV-C RNA by reverse transcription-PCR.
This frequency lies within the range reported for comparable
non-remunerated blood donor populations in other countries,
such as Germany (1.3%—1.9%), France (4.2%), the United
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Figure 1. Retrospective testing for HGV/GBV-C RNA of archived blood donations from 23 blood donors identified as HGV/GBV-C-infected
in November-December 1996. 6 donors above horizontal line are those with persistent infection throughout observation period. •, HGV/GBV-













States (1 7%), Australia (4%), and Japan (0.5%—1.2%) [2, 5-8],
The male-to-female ratio of HGV/GBV-C-infected donors was
11:12, different from the 3:1 ratio observed among blood do¬
nors infected with HCV in Scotland or elsewhere. The high
prevalence of HGV/GBV-C infection and the absence of sig¬
nificant disclosed parenteral risk factors for infection in the
HGV/GBV-C-infected donors strongly suggests other routes
of transmission.
Among other proposed routes of transmission ofHGV/GBV-
C, evidence for transmission by sexual contact includes the
finding of high prevalences of infection in persons with sexually
transmitted disease or with other evidence of sexual exposure
with multiple partners [9]. Against this hypothesis is the
absence of detectable transmission of HGV/GBV-C (either by
PCR or serology) to the sex partners of 5 infected donors.
Mother-to-child transmission has been documented by the
frequent detection of HGV/GBV-C viremia (20%-70%) in
children born of infected mothers [10]. However, the obser¬
vation of de novo infection in at least 17 of the 23 HGV/
GBV-C-infected blood donors in the current study indicates
that the acquisition of infection occurred predominantly in
adulthood.
The frequent finding of HGV/GBV-C-positive samples
among archived donations from the infected donors indicates
that infection may persist for several years (at least 10 years in
p4). The results of this retrospective study are consistent with
the finding of persistent infection of at least 2 years among 4
of 5 Australian blood donors [7] and the documented pro¬
longed infection in varying proportions of persons infectedwith
HGV/GBV-C through blood transfusion or treatment with
blood products [11, 12].
A surprising finding that arose from the retrospective study
was the relatively high incidence of HGV/GBV-C infection.
The calculated rate (170-200 infections per 100,000 person-
years) contrasts strongly with rates of acquisition of HCV
(1.8-10 per 100,000), HIV (1.3-4.0 per 100,000), and HBV
(1.7-4.0 per 100,000) in similar non-remunerated blood donor
populations in Europe, the United States, Japan, and Australia.
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If, in the future, donations were to be screened for HGV/
GBV-C RNA by PCR, the number of new infections detected
would place severe constraints on the size of the pool used. For
example, even if all persistently infected donors were excluded,
new infections with HGV/GBV-C over a mean donation in¬
terval of 6 months would lead to contamination of 50% of
pools containing 500 component donations and 10% of pools
containing 100 components.
The asymptomatic nature ofHGV/GBV-C was directly dem¬
onstrated by our clinical examination of the infected donors.
Two donors showed minimal elevation of ALT levels, but the
mean level (20 IU/mL) and all other liver function tests were
in the normal range. No subject had a previous history of
acute hepatitis or jaundice. No donor had any abnormality on
clinical examination, other than arthralgia in 5 persons. How¬
ever, there was no consistent pattern of joint involvement, and
larger studies would be required to make a more substantive
link.
These findings are consistent with the absence of clinically
or biochemically apparent liver disease in those infected by
blood transfusion [13-15]. For example, of 79 with posttrans¬
fusion hepatitis, only 3 were infected with HGV/GBV-C alone
[14], all had mild, asymptomatic hepatitis, and the absence of
any correlation between ALT elevation and detection of HGV/
GBV-C by PCR suggests other causes for the observed hepa¬
titis. A difficulty encountered in investigating the HGV/GBV-
C-infected donors in the current study arose from the current
lack of information about the tropism and likely disease as¬
sociations of HGV/GBV-C in vivo. Although HGV/GBV-C
RNA can be detected in the liver, there is little evidence for
its replication there. Thirteen of 17 HGV/GBV-C-positive do¬
nors showed relatively high levels of HGV/GBV-C RNA in
saliva and a mean ratio to levels detected in plasma of
—1:1000. The frequency of detection and ratio to levels detected
in plasma contrasts with that documented for HCV and sug¬
gests that replication of HGV/GBV-C in the respiratory or gas¬
trointestinal tracts may occur. None of them had any history
of respiratory symptoms or disease, although its secretion into
saliva may represent a route of transmission, as documented
for human cytomegalovirus and other herpesviruses.
In conclusion, this study demonstrates that HGV/GBV-C
infection is common among our donor population but is not
associated with significant hepatic disease or symptoms. We
have not been able to identify a risk factor for infection in the
majority of HGV-positive donors. HGV/GBV-C RNA was
present in the plasma in the majority of subjects for several
years and was likely to have been transfused in a large number
of blood components. These findings will enable recipients of
HGV/GBV-C-positive blood to be identified and the clinical
sequelae investigated. In the interim, in the absence of clinico-
pathologic data suggesting significant morbidity in HGV/
GBV-C-infected donors, blood donors should not be screened
for HGV/GBV-C.
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